Omnicell (OMCL) 10-Q 8 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information Document and Entity Information	3 Months Ended
	Sep. 30, 2013	Nov. 01, 2013
Entity Information [Line Items]	'	'
Entity Registrant Name	'OMNICELL, Inc	'
Entity Central Index Key	'0000926326	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Well-known Seasoned Issuer	'No	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	35,614,670
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$116,190	$62,313
Accounts receivable, net of allowances of $579 and $772 at September 30, 2013 and December 31, 2012, respectively	63,999	55,116
Inventories	30,705	26,903
Prepaid expenses	17,053	15,392
Deferred tax assets	11,860	11,860
Other current assets	8,052	9,172
Total current assets	247,859	180,756
Property and equipment, net	33,492	34,107
Non-current net investment in sales-type leases	12,398	13,228
Goodwill	111,343	111,407
Other intangible assets	82,530	85,550
Non-current deferred tax assets	1,293	993
Other assets	17,069	15,778
Total assets	505,984	441,819
Current liabilities:	'	'
Accounts payable	24,717	18,255
Accrued compensation	12,876	11,613
Accrued liabilities	14,019	11,988
Deferred service revenue	22,247	20,449
Deferred gross profit	25,206	20,772
Total current liabilities	99,065	83,077
Non-current deferred service revenue	17,657	19,892
Non-current deferred tax liabilities	26,053	26,491
Other long-term liabilities	5,423	4,809
Total liabilities	148,198	134,269
Stockholders' equity:	'	'
Total stockholders' equity	357,786	307,550
Total liabilities and stockholders' equity	$505,984	$441,819

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accounts receivable, allowances	$579	$722

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues:	'	'	'	'
Product revenues	$75,508	$67,446	$220,325	$175,239
Services and other revenues	18,531	16,885	54,510	48,619
Total revenues	94,039	84,331	274,835	223,858
Cost of revenues:	'	'	'	'
Cost of product revenues	33,977	30,636	103,810	79,532
Cost of services and other revenues	8,022	7,608	24,250	23,114
Total cost of revenues	41,999	38,244	128,060	102,646
Gross profit	52,040	46,087	146,775	121,212
Operating expenses:	'	'	'	'
Research and development	6,561	5,545	21,665	17,538
Selling, general and administrative	34,762	29,316	100,866	86,382
Total operating expenses	41,323	34,861	122,531	103,920
Income from operations	10,717	11,226	24,244	17,292
Interest and other income (expense), net	25	34	-134	57
Income before provision for income taxes	10,742	11,260	24,110	17,349
Provision for income taxes	2,987	4,340	6,954	6,703
Net income	$7,755	$6,920	$17,156	$10,646
Net income per share:	'	'	'	'
Net income per share-basic	$0.22	$0.21	$0.50	$0.32
Net income per share - diluted	$0.21	$0.20	$0.48	$0.31
Weighted average shares outstanding:	'	'	'	'
Basic (in shares)	35,133	33,193	34,499	33,316
Diluted (in shares)	36,190	34,068	35,466	34,241

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net income	$7,755	$6,920	$17,156	$10,646
Other comprehensive income, net of tax:	'	'	'	'
Unrealized holding losses arising during the period	0	0	0	-1
Changes in fair value of foreign currency forward hedges	0	0	-65	65
Foreign currency translation adjustment	217	70	21	54
Other comprehensive income (loss)	217	70	-44	118
Comprehensive income	$7,972	$6,990	$17,112	$10,764

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Acquistiion consideration accrued as goodwill and accrued liabilities	$0	($1,482)
Cash flows from operating activities:	'	'
Net income	17,156	10,646
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	13,732	9,247
Loss on disposal of fixed assets	289	28
Asset Impairment Charges	1,759	0
Provision for (recovery of) receivable allowance	110	410
Share-based compensation expense	8,387	6,781
Income tax benefits from employee stock plans	1,707	1,638
Excess tax benefits from employee stock plans	-2,827	-2,336
Provision for excess and obsolete inventories	911	509
Deferred income taxes	-737	-1,084
Changes in operating assets and liabilities:	'	'
Accounts receivable, net	-9,004	-7,103
Inventories	-4,713	2,924
Prepaid expenses	-1,661	-3,453
Other current assets	-394	921
Net investment in sales-type leases	1,313	-1,493
Other assets	307	-13
Accounts payable	6,462	2,131
Accrued compensation	1,263	802
Accrued liabilities	2,031	-1,719
Deferred service revenue	-403	2,117
Deferred gross profit	4,434	5,377
Other long-term liabilities	615	1,147
Net cash provided by operating activities	40,737	27,477
Cash flows from investing activities:	'	'
Maturities of short-term investments	0	8,122
Acquisition of intangible assets and intellectual property	-225	-303
Software development for external use	-5,694	-3,118
Purchases of property and equipment	-7,817	-9,560
Business acquisition, net of cash acquired	0	-156,312
Net cash used in investing activities	-13,736	-161,171
Cash flows from financing activities:	'	'
Proceeds from issuance of common stock under employee stock purchase and stock option plans	24,020	6,777
Stock repurchases	0	-12,363
Excess tax benefits from employee stock plans	2,827	2,336
Net cash provided from financing activities	26,847	-3,250
Effect of exchange rate changes on cash and cash equivalents	29	0
Net (decrease) increase in cash and cash equivalents	53,877	-136,944
Cash and cash equivalents at beginning of period	62,313	191,762
Cash and cash equivalents at end of period	$116,190	$54,818

Organization_and_Summary_of_Si

Organization and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization and Summary of Significant Accounting Policies	'
	Organization and Summary of Significant Accounting Policies
	Description of the Company. Omnicell, Inc. ("Omnicell," "our," "us," "we," or the "Company") was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. Our major products are automated medication and supply control systems which are sold in our principal market, which is the healthcare industry. Our market is primarily located in the United States. On May 21, 2012, we completed our acquisition of MedPak Holdings, Inc. ("MedPak"). MedPak is the parent company of MTS Medication Technologies, Inc. ("MTS"), a worldwide provider of medication adherence packaging systems. This acquisition aligns us with the long-term trends of the healthcare market to manage the health of patients across the continuum of care. We now serve both the acute care and non-acute care markets. Please refer to Note 14, "Business Acquisition" for more information regarding the transaction.
	Basis of presentation. These interim condensed consolidated financial statements are unaudited but reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of Omnicell and its subsidiaries as of September 30, 2013, the results of their operations and comprehensive income for the three and nine months ended September 30, 2013 and 2012 and their cash flows for the nine months ended September 30, 2013 and 2012. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2012.

Net_Income_Per_Share

Net Income Per Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Net Income Per Share	'
		Net Income Per Share
	Basic net income per share is computed by dividing net income for the period by the weighted average number of shares outstanding during the period, less shares subject to repurchase. Diluted net income per share is computed by dividing net income for the period by the weighted average number of shares, less shares subject to repurchase, plus, if dilutive, potential common stock outstanding during the period. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards and restricted stock units computed using the treasury stock method. Since their impact is anti-dilutive, we excluded 1,178,755 and 2,067,273 shares from the calculations of diluted net income per share for the nine months ended September 30, 2013 and 2012, respectively.
	The calculation of basic and diluted net income per share is as follows (in thousands, except per share amounts):
		Three Months Ended September 30,				Nine Months Ended September 30,
		2013		2012		2013		2012
	Basic:
	Net income	$	7,755	$	6,920	$	17,156	$	10,646
	Weighted average shares outstanding — basic	35,133		33,193		34,499		33,316
	Net income per share — basic	$	0.22	$	0.21	$	0.5	$	0.32
	Diluted:
	Net income	$	7,755	$	6,920	$	17,156	$	10,646
	Weighted average shares outstanding — basic	35,133		33,193		34,499		33,316
	Add: Dilutive effect of employee stock plans	1,057		875		967		925
	Weighted average shares outstanding — diluted	36,190		34,068		35,466		34,241
	Net income per share — diluted	$	0.21	$	0.2	$	0.48	$	0.31

Cash_and_Cash_Equivalents_Shor

Cash and Cash Equivalents, Short-term Investments and Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2013
Cash and Cash Equivalents [Abstract]	'
Cash and Cash Equivalents, Short-term Investments and Fair Value of Financial Instruments	'
	Cash and Cash Equivalents and Fair Value of Financial Instruments
	Cash and cash equivalents consist of the following significant investment asset classes, with disclosure of amortized cost, gross unrealized gains and losses and fair value as of September 30, 2013 and December 31, 2012 (in thousands):
		30-Sep-13
		Amortized		Unrealized		Unrealized		Fair Value		Cash / Cash		Security
		Cost		Gains		Losses				Equivalents		Classification
	Cash	$	51,415	$	—	$	—	$	51,415	$	51,415	N/A
	Money market fund	64,775		—		—		64,775		64,775		Available for sale
	Total cash and cash equivalents	$	116,190	$	—	$	—	$	116,190	$	116,190
	c	31-Dec-12
		Amortized		Unrealized		Unrealized		Fair Value		Cash / Cash		Security
		Cost		Gains		Losses				Equivalents		Classification
	Cash	$	23,422	$	—	$	—	$	23,422	$	23,422	N/A
	Money market fund	38,892		—		1		38,891		38,891		Available for sale
	Total cash and cash equivalents	$	62,314	$	—	$	1	$	62,313	$	62,313
	The money market fund is a daily-traded cash equivalent with a price of $1.00, making it a Level 1 asset class, and its carrying cost closely approximates fair value. As demand deposit (cash) balances vary with the timing of collections and payments, the money market fund can cover any surplus or deficit, and thus is considered Available-for-sale.
	The following table displays the financial assets measured at fair value, on a recurring basis, with money market funds recorded within cash and cash equivalents (in thousands):
		Quoted Prices in Active		Significant Other		Significant		Total Fair
		Markets for Identical		Observable Inputs		Unobservable		Value
		Instruments		(Level 2)		Inputs
		(Level 1)				(Level 3)
	At September 30, 2013
	Money market fund	$	64,775	$	—	$	—	$	64,775
	Total	$	64,775	$	—	$	—	$	64,775
	At December 31, 2012
	Money market fund	$	38,891	$	—	$	—	$	38,891
	Total	$	38,891	$	—	$	—	$	38,891
	Current assets and current liabilities are recorded at amortized cost, which approximates fair value due to the short-term maturities implied.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories
	Inventories consist of the following (in thousands):
		September 30,		December 31,
		2013		2012
	Raw materials	$	11,120	$	9,994
	Work in process	963		385
	Finished goods	18,622		16,524
	Total	$	30,705	$	26,903

Property_and_Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property and Equipment	'
	Property and Equipment
	Property and equipment consist of the following (in thousands):
		September 30,			December 31,
		2013			2012
	Equipment	$	35,483		$	32,528
	Furniture and fixtures	5,149			5,126
	Leasehold improvements	7,356			6,992
	Purchased software	19,800			19,870
	Capital in process	3,491			2,693
		71,279			67,209
	Accumulated depreciation and amortization	(37,787		)	(33,102		)
	Property and equipment, net	$	33,492		$	34,107
	Depreciation and amortization of property and equipment totaled approximately $2.6 million and $2.2 million for the three months ended September 30, 2013 and 2012, respectively. Depreciation and amortization of property and equipment totaled approximately $8.2 million and $5.7 million for the nine months ended September 30, 2013 and 2012, respectively.

Net_Investment_in_SalesType_Le

Net Investment in Sales-Type Leases	9 Months Ended
	Sep. 30, 2013
Net Investment in Sales-Type Leases Disclosure	'
Net Investment Sales-Type Leases Disclosure [Text Block]	'
	Net Investment in Sales-Type Leases
	Our sales-type leases are for terms generally up to five years. Sales-type lease receivables are collateralized by the underlying equipment. The components of our net investment in sales-type leases are as follows (in thousands):
		September 30,			December 31,
		2013			2012
	Net minimum lease payments to be received	$	18,788		$	19,665
	Less unearned interest income portion	1,157			1,205
	Net investment in sales-type leases	17,631			18,460
	Less current portion(1)	5,233			5,232
	Non-current net investment in sales-type leases(2)	$	12,398		$	13,228
	(1)     A component of other current assets. This amount is net of allowance for doubtful accounts of $0.1 million as of September 30, 2013 and $0.5 million as of December 31, 2012.
	(2)     This amount is net of allowance for doubtful accounts of $0.1 million as of September 30, 2013 and $0.1 million as of December 31, 2012.
	The minimum lease payments under sales-type leases as of September 30, 2013 were as follows (in thousands):
	2013 (remaining three months)	$	1,640
	2014	5,495
	2015	4,536
	2016	3,341
	2017	2,603
	Thereafter	1,173
	Total	$	18,788
	The following table summarizes the credit losses and recorded investment in sales-type leases, excluding unearned interest (in thousands):
		Allowance for Credit Losses			Recorded Investment				Recorded Investment
					in Sales-type Leases Gross				in Sales-type Leases Net
	Credit loss disclosure for September 30, 2013:
	Accounts individually evaluated for impairment	$	22		$	22			$	—
	Accounts collectively evaluated for impairment	152			17,783				17,631
	Ending balances: September 30, 2013	$	174		$	17,805			$	17,631
	Credit loss disclosure for December 31, 2012:
	Accounts individually evaluated for impairment	$	489		$	489			$	—
	Accounts collectively evaluated for impairment	118			18,578				18,460
	Ending balances: December 31, 2012	$	607		$	19,067			$	18,460
	The following table summarizes the activity for the allowance for credit losses for the investment in sales-type leases for the three and nine months ended September 30, 2013 and 2012 (in thousands):
		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2012			2013			2012
	Allowance for credit losses, beginning of period	$	184		$	659		$	607		$	284
	Current period provision	15			4			34			426
	Direct write-downs charged against the allowance	—			—			(413		)	—
	Recoveries of amounts previously charged off	(25		)	(26		)	(54		)	(73		)
	Allowance for credit losses, end of period	$	174		$	637		$	174		$	637

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Other Intangible Assets	'
	Goodwill and Other Intangible Assets
	Under ASC 350, Intangibles—Goodwill and Other, goodwill is not subject to amortization. We evaluate goodwill for impairment at least annually or more frequently if events and changes in circumstances suggest that the carrying amount may not be recoverable.
	Activity in goodwill by reporting unit, which is the same for our operating segments, for the nine months ended September 30, 2013 consists of the following (in thousands):
		Goodwill at December 31, 2012		Adjustments to Goodwill			Goodwill at September 30, 2013
	Reporting units:
	Acute Care	$	28,543	$	—		$	28,543
	Non-Acute Care	82,864		(64		)	82,800
	Total	$	111,407	$	(64	)	$	111,343
	Goodwill acquired reflects the May 21, 2012 acquisition of MedPak by Omnicell. MedPak is the parent company of MTS, a worldwide provider of medication adherence packaging systems. The acquired goodwill was assigned to our new reporting unit called Non-Acute Care, created as a result of the MTS acquisition. During the first quarter of 2013, we reduced goodwill by approximately $0.1 million due to the adjustment to the fair value of an acquired foreign currency forward contract previously carried in a component of stockholder's equity.
	There were no indefinite-life intangibles at either September 30, 2013 or December 31, 2012. Finite-life intangible assets consist of the following (in thousands):
		September 30, 2013							December 31, 2012
		Gross					Net		Gross				Net
		Carrying		Accumulated			Carrying		Carrying		Accumulated		Carrying		Amortization
		Amount		Amortization			Amount		Amount		Amortization		Amount		Life
	Finite-lived intangibles:
	Customer relationships	$	54,730	$	4,698		$	50,032	$	54,730	$	3,081	$	51,649	5-30 years
	Acquired technology	27,580		2,230			25,350		27,580		1,128		26,452		3-20 years
	Patents	1,363		244			1,119		1,217		259		958		20 years
	Trade name	6,890		861			6,029		6,890		414		6,476		3-12 years
	Non-compete agreements	60		60			—		60		45		15		3 years
	Total finite-lived intangibles	$	90,623	$	8,093		$	82,530	$	90,477	$	4,927	$	85,550
	Amortization expense totaled $1.1 million and $1.1 million for the three months ended September 30, 2013 and 2012, respectively. Amortization expense totaled $3.2 million and $1.8 million for the nine months ended September 30, 2013 and 2012, respectively. The amortization of acquired technology is included within product cost of sales; other acquired intangibles are usually amortized within selling, general and administrative expenses.
	Estimated annual expected amortization expense of the finite-lived intangible assets at September 30, 2013 was as follows (in thousands):
	2013 (remaining three months)	$	1,059
	2014	4,229
	2015	4,204
	2016	3,854
	2017	3,818
	2018	3,711
	Thereafter	61,655
	Total	$	82,530

Accrued_Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2013
Accrued Liabilities, Current [Abstract]	'
Accrued Liabilities [Text Block]	'
	Accrued Liabilities
	Accrued liabilities consist of the following (in thousands):
		September 30,		December 31,
		2013		2012
	Rebates and lease buyouts	$	3,379	$	3,179
	Advance payments from customers	4,272		2,829
	Accrued Group Purchasing Organization (GPO) fees	2,492		2,278
	Technology license purchase obligation, current portion	1,500		1,750
	Taxes payable (receivable)	774		555
	Other	1,602		1,397
	Total	$	14,019	$	11,988

Deferred_Gross_Profit

Deferred Gross Profit	9 Months Ended
	Sep. 30, 2013
Deferred Gross Profit [Abstract]	'
Deferred Gross Profit [Text Block]	'
	Deferred Gross Profit
	Deferred gross profit consists of the following (in thousands):
		September 30,			December 31,
		2013			2012
	Sales of medication and supply dispensing systems and packaging equipment, which have been delivered and invoiced but not yet installed	$	40,919		$	30,138
	Cost of revenues, excluding installation costs	(15,713		)	(9,366		)
	Deferred gross profit	$	25,206		$	20,772

Commitments

Commitments	9 Months Ended
	Sep. 30, 2013
Commitments	'
Commitments Disclosure [Text Block]	'
	Commitments
	At September 30, 2013, the minimum payments under our operating leases for each of the five succeeding fiscal years were as follows (in thousands):
	2013 (remaining three months)	$	1,462
	2014	5,722
	2015	5,476
	2016	5,150
	2017	4,468
	2018	4,298
	Thereafter	16,600
	Total	$	43,176
	In October 2011, we entered into a lease agreement for approximately 100,000 square feet of office space. Pursuant to the lease agreement, the landlord constructed a single, three-story building of rentable space in Mountain View, California which we now lease and which serves as our headquarters. The term of the lease agreement, which commenced in November 2012, is for a period of 10 years, with a base lease commitment of approximately $40.0 million. We have two options to extend the term of the lease agreement at market rates. Each extension is for an additional 60 month term.
	In March 2012, we entered into a lease agreement for approximately 46,000 square feet of manufacturing, distribution and office space located in Milpitas, California which commenced in October, 2012. The term of the lease agreement is for a period of 60 months, with a base lease commitment of approximately $1.8 million and a single 60 month extension option.
	In connection with the acquisition of MTS, we assumed responsibility for 132,500 square feet of manufacturing, warehousing and office space in St. Petersburg, Florida. The remaining term of the original lease agreement was for a period of 12 years, which expires in September 2016 and at the time of the MTS acquisition, with a base lease commitment of approximately $3.9 million. We have two options to extend the term of the lease agreement at market rates. Each extension is for an additional 60 month term.
	In Leeds, United Kingdom, we lease an office and distribution center of approximately 16,500 square feet. The remaining term of the original ten year lease agreement is through June 8, 2021, with no extension options. The base lease commitment at the time of the MTS acquisition, converted from British Pounds at the conversion rate then in effect, was approximately $1.2 million.
	We also have smaller rented offices in Strongsville, Ohio, Nashville, Tennessee, Waukegan, Illinois, the United Arab Emirates, the People's Republic of China and the Federal Republic of Germany.
	We purchase components from a variety of suppliers and use contract manufacturers to provide manufacturing services for our products. During the normal course of business, we issue purchase orders with estimates of our requirements several months ahead of the delivery dates. Our near-term commitments to our contract manufacturers and suppliers totaled $7.5 million as of September 30, 2013.
	At September 30, 2013, we have recorded $4.7 million for uncertain tax positions under long term liabilities in accordance with GAAP, summarized under Note 1, “Organization and Summary of Significant Accounting Policies.” As these liabilities do not reflect actual tax assessments, the timing and amount of payments we might be required to make will depend upon a number of factors. Accordingly, as the timing and amount of payment cannot be estimated, we do not present this in a commitments table.

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Contingencies	'
	Contingencies
	Legal Proceedings
	On March 8, 2013, Bobbi Polanco (“Polanco”) filed a putative class action complaint in the United States District Court for the District of New Jersey against Omnicell and certain of our customers (Case No. 1:13-cv-01417-NLH-KLM) alleging breach of state security notification laws, violations of state consumer fraud laws, fraud, negligence and conspiracy relating to the theft of an Omnicell electronic device containing medication dispensing cabinet log files, including certain patient health information, and subsequent notification of this unauthorized disclosure of personal health information. Polanco is seeking an injunction against the defendants to prevent each of them from committing the acts complained of in the future and monetary damages, costs and expenses. On May 2, 2013, the United States District Court for the District of New Jersey entered an order to show cause which provided, in relevant part, that Polanco is required to show cause as to why the case should not be dismissed for lack of subject matter jurisdiction. On May 13, 2013, Polanco filed an amended complaint. On May 31, 2013, Omnicell filed a motion to dismiss the complaint on the grounds that Polanco failed to satisfy constitutional standing requirements and that she failed to state a claim against Omnicell  for violating  state data breach notification statutes, consumer fraud, common law fraud, negligence and conspiracy. Omnicell also joined in the arguments of the other defendants seeking dismissal. On July 1, 2013, Polanco filed an opposition to the motions to dismiss. On July 15, 2013, Omnicell filed its reply to the opposition from Polanco. Omnicell is currently awaiting a decision from the court and intends to defend the matter vigorously.
	As required under ASC 450, Contingencies, we accrue for contingencies when we believe that a loss is probable and that we can reasonably estimate the amount of any such loss. We have not recorded any accrual for contingent liabilities associated with the legal proceedings described above based on our belief that any potential loss, while reasonably possible, is not probable. Further, any possible range of loss in these matters cannot be reasonably estimated at this time. We believe that we have valid defenses with respect to legal proceedings pending against us. However, litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of this contingency or because of the diversion of management's attention and the creation of significant expenses.
	Guarantees
	As permitted under Delaware law and our certificate of incorporation and bylaws, we have agreed to indemnify our directors and officers against certain losses that they may suffer by reason of the fact that such persons are, were or become our directors or officers. The term of the indemnification period is for the director’s or officer’s lifetime and there is no limit on the potential amount of future payments that we could be required to make under these indemnification agreements. We have purchased a directors’ and officers’ liability insurance policy that may enable us to recover a portion of any future payments that we may be required to make under these indemnification agreements. Assuming the applicability of coverage and the willingness of the insurer to assume coverage and subject to certain retention, loss limits and other policy provisions, we believe it is unlikely that we will be required to pay any material amounts pursuant to these indemnification obligations. However, no assurances can be given that the insurers will not attempt to dispute the validity, applicability or amount of coverage without expensive and time-consuming litigation against the insurers.
	Additionally, we undertake indemnification obligations in our ordinary course of business in connection with, among other things, the licensing of our products and the provision of our support services. In the ordinary course of our business, we have in the past and may in the future agree to indemnify another party, generally our business affiliates or customers, against certain losses suffered or incurred by the indemnified party in connection with various types of claims, which may include, without limitation, claims of intellectual property infringement, certain tax liabilities, our gross negligence or intentional acts in the performance of support services and violations of laws. The term of these indemnification obligations is generally perpetual. In general, we attempt to limit the maximum potential amount of future payments that we may be required to make under these indemnification obligations to the amounts paid to us by a customer, but in some cases the obligation may not be so limited. In addition, we have in the past and may in the future warrant to our customers that our products will conform to functional specifications for a limited period of time following the date of installation (generally not exceeding 30 days) or that our software media is free from material defects. Sales contracts for certain of our medication packaging systems often include limited warranties for up to six months, but the periodic activity and ending warranty balances we record have historically been immaterial.
	From time to time, we may also warrant that our professional services will be performed in a good and workmanlike manner or in a professional manner consistent with industry standards. We generally seek to disclaim most warranties, including any implied or statutory warranties such as warranties of merchantability, fitness for a particular purpose, title, quality and non-infringement, as well as any liability with respect to incidental, consequential, special, exemplary, punitive or similar damages. In some states, such disclaimers may not be enforceable. If necessary, we would provide for the estimated cost of product and service warranties based on specific warranty claims and claim history. We have not been subject to any significant claims for such losses and have not incurred any material costs in defending or settling claims related to these indemnification obligations. Accordingly, we believe it is unlikely that we will be required to pay any material amounts pursuant to these indemnification obligations or potential warranty claims and, therefore, no material liabilities have been recorded for such indemnification obligations as of September 30, 2013 or December 31, 2012.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity	'
	Stockholders’ Equity
	Treasury Stock
	2008 Stock Repurchase Program
	In February 2008, our Board of Directors authorized a stock repurchase program (the “2008 Repurchase Program”) for the repurchase of up to $90.0 million of our common stock. The timing, price and volume of the repurchases have been based on market conditions, relevant securities laws and other factors.
	There were no shares repurchased during both the three and nine months ended September 30, 2013 under the 2008 Repurchase Program. During the three months ended September 30, 2012, we repurchased 393,031 shares through the 2008 Repurchase Program at an average cost of $13.49 per share, including commissions, compared to 505,137 shares repurchased in the three months ended June 30, 2012 at an average cost of $13.98 per share, including commissions. For the nine months ended September 30, 2012, we repurchased 898,168 shares at an average cost of 13.76 per share, including commissions.
	From the inception of the 2008 Repurchase Program in February 2008 through September 30, 2013, we have repurchased a total of 5,853,975 shares at an average cost of $15.37 per share through open market purchases. As of September 30, 2013, we have completed the 2008 Repurchase Program having repurchased $90.0 million of our common stock.
	2012 Stock Repurchase Program
	On August 1, 2012, our Board of Directors established a new stock repurchase program (the “2012 Repurchase Program”) authorizing share repurchases of up to $50.0 million of our common stock, with no termination date. The timing, price and volume of repurchases will be based on market conditions, relevant securities laws and other factors. The stock repurchases may be made from time to time on the open market, in privately negotiated transactions or pursuant to a Rule 10b-18 plan. The stock repurchase program does not obligate Omnicell to repurchase any specific number of shares, and Omnicell may terminate or suspend the repurchase program at any time.
	Through September 30, 2013, we have not repurchased any shares through the 2012 Repurchase Program.

Stock_Option_Plans_and_ShareBa

Stock Option Plans and Share-Based Compensation	9 Months Ended
	Sep. 30, 2013
Stock Option Plans and Share-Based Compensation [Abstract]	'
Stock Option Plans and Share-Based Compensation	'
	Stock Option Plans and Share-Based Compensation
	Stock Option Plans
	Description of Share-Based Plans
	Equity Incentive Plan
	On May 19, 2009, at our 2009 Annual Meeting of Stockholders (the "2009 Annual Meeting") our stockholders approved the Omnicell, Inc. 2009 Equity Incentive Plan (the "2009 Plan") which authorized 2,100,000 shares to be issued. The 2009 Plan provides for the issuance of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards and other stock awards to our employees, directors and consultants.
	The 2009 Plan succeeded the 1999 Equity Incentive Plan, as amended, the 2003 Equity Incentive Plan, as amended, and the 2004 Equity Incentive Plan (collectively, the "Prior Plans"). No additional awards will be granted under any of the Prior Plans; however, all outstanding stock awards granted under the Prior Plans continue to be subject to the terms and conditions as set forth in the agreements evidencing such stock awards. For purposes of determining future common shares available for grant, for each share granted as a full-value award, including restricted stock and restricted stock units ("RSUs") performance stock awards, the shares available for grant were reduced by 1.4 shares. Equity awards granted as stock options and stock appreciation rights reduce the shares available for grant by one share.
	On December 16, 2010, at a Special Meeting of Stockholders, our stockholders approved an amendment to increase the number of shares of common stock authorized for issuance under the 2009 Plan by 2,600,000 shares and to provide that the number of common stock shares available for issuance under the 2009 Plan be reduced by 1.8 shares for each share granted as a full-value award granted on and after October 1, 2010. For each share granted as a full-value award granted prior to October 1, 2010, future shares available for grants under the 2009 Plan were reduced by 1.4 shares. Awards granted as stock options and stock appreciation rights continue to reduce the number of shares available for issuance under the 2009 Plan on a one-for-one basis. On May 21, 2013, at our Annual Meeting of Stockholders, our stockholders approved an amendment to increase the number of shares of common stock authorized for issuance under the 2009 Plan by 2,500,000 shares.
	Options granted under the 2009 Plan generally become exercisable over periods of up to 4 years , generally with one-fourth of the shares vesting one year from the vesting commencement date with respect to initial grants, and the remaining shares vesting in 36 equal monthly installments thereafter; however our board of directors may impose different vesting terms at its discretion on any award. Options under the 2009 Plan generally expire 10 years from the date of grant. We also grant both restricted stock and restricted stock units to participants under the 2009 Plan. The Board of Directors determines the award amount, the vesting provisions and the expiration period (not to exceed ten years) for each grant. Grants of restricted stock to non-employee directors are granted on the date of our annual meeting of stockholders and vest in full on the date of our next annual meeting of stockholders, provided such non-employee director remains a director on such date. The fair value of the stock on the date of issuance is amortized to expense from the date of grant to the date of vesting. RSUs granted to employees generally vest over a period of four years and are expensed ratably on a straight-line basis over the vesting period. We consider the dilutive impact of options, restricted stock and restricted stock units in our diluted net income per share calculation.
	The Board of Directors shall administer the 2009 Plan unless and until the Board of Directors delegates administration to a committee. Our Board of Directors has delegated administration of the 2009 Plan to the Compensation Committee of the Board of Directors and the 2009 Plan is generally administered by such committee. The Board of Directors may suspend or terminate the 2009 Plan at any time. The Board of Directors may also amend the 2009 Plan at any time or from time to time. However, no amendment will be effective unless approved by our stockholders after its adoption by our Board of Directors to the extent stockholder approval is necessary to satisfy the applicable listing requirements of NASDAQ.
	If we sell, lease or dispose of all or substantially all of our assets, or we are acquired pursuant to a merger or consolidation, then the surviving entity may assume or substitute all outstanding awards under the 2009 Plan. If the surviving entity does not assume or substitute these awards, then generally the stock awards will immediately and fully vest.
	At September 30, 2013, a total of 3,353,608 shares of common stock were reserved for future issuance under the 2009 Plan. At September 30, 2013, $6.0 million of total unrecognized compensation cost related to non-vested stock options was expected to be recognized over a weighted average period of 2.6 years.
	A summary of aggregate option activity for the nine months ended September 30, 2013 is presented below:
	Options:		Number of Shares			Weighted-
						Average
						Exercise Price
			(in thousands)
	Outstanding at December 31, 2012		4,470			$	14.06
	Granted		296			$	18.1
	Exercised		(1,450	)		$	12.59
	Forfeited		(75	)		$	14.4
	Expired		(56	)		$	15.68
	Outstanding at September 30, 2013		3,185			$	15.07
	Exercisable at September 30, 2013		2,186			$	14.85
	Restricted Stock and Time-based Restricted Stock Units
	The non-employee members of our Board of Directors are granted restricted stock on the day of our annual meeting of stockholders and such shares of restricted stock vest on the date of the subsequent year’s annual meeting of stockholders, provided such non-employee director remains a director on such date.
	Restricted stock units (“RSUs”) are granted to certain of our employees and generally vest over a period of four years and are expensed ratably on a straight-line basis over the vesting period. The fair value of both restricted stock and RSUs granted pursuant to our stock option plans is the product of the number of shares granted and the grant date fair value of our common stock. Our unrecognized compensation cost related to non-vested restricted stock at September 30, 2013 was approximately $0.6 million and is expected to be recognized over a weighted-average period of 0.6 years. Expected future compensation expense relating to RSUs outstanding on September 30, 2013 is $4.8 million over a weighted-average period of 2.2 years.
	A summary of activity of both restricted stock and RSUs for the nine months ended September 30, 2013 is presented below:
		Restricted Stock						Restricted Stock Units
		Number of			Weighted-Average			Number of		Weighted-Average
		Shares			Grant Date			Shares		Grant Date
					Fair Value Per					Fair Value Per
					Share					Share
		(in thousands)						(in thousands)
	Non-vested, December 31, 2012	58			$	14.19		389		$	14.09
	Granted	55			$	18.2		125		$	18.12
	Vested	(61	)		$	14.23		(98	)	$	13.9
	Forfeited	—			$	—		(21	)	$	14.07
	Non-vested, September 30, 2013	52			$	18.43		395		$	15.41
	Performance-Based Restricted Stock Units
	In 2011, we began incorporating performance-based restricted stock units ("PSUs") as an element of our executive compensation plans. For 2011, we granted 100,000 PSUs; however, pursuant to their terms, 120,000 PSUs ultimately became eligible for vesting based on the achievement of a certain level of shareholder return for 2011 as described below. In 2012, we granted 125,000 PSUs of which 62,500 became eligible for vesting based on the achievement of a certain level of stockholder return for 2012 as described below.
	Our unrecognized compensation cost related to non-vested performance-based restricted stock units at September 30, 2013 was approximately $1.5 million and is expected to be recognized over a weighted-average period of 1.3 years. For the three months ended September 30, 2013 and 2012, we recognized $0.4 million and $0.2 million, respectively, of compensation expense for the performance-based restricted stock units. For the nine months ended September 30, 2013 and 2012, we recognized $1.2 million and $0.8 million, respectively, of compensation expense for the performance-based restricted stock units.
	The accounting guidance for awards with market conditions differs from that for awards with service conditions only or service and performance conditions. Because the grant date fair value of an award containing market conditions is calculated as the expected value, averaging over all possible outcomes, the measured expense is amortized over the service period, regardless of whether the market condition is ever actually met.
	The fair value of a PSU award is the average of trial-specific values of the award over each of one million Monte Carlo trials. Each trial-specific value is the market value of the award at the end of the one-year performance period discounted back to the grant date. The market value of the award for each trial at the end of the performance period is the product of (a) the per share value of Omnicell stock at the end of the performance period and (b) the number of shares that vest. The number of shares that vest at the end of the performance period depends on the percentile ranking of the total stockholder return for Omnicell stock over the performance period relative to the total stockholder return of each of the other companies in the NASDAQ Healthcare Index (the "Index") as shown in the tables below.
	Vesting for the PSU awards is based on the percentile placement of our total stockholder return among the companies listed in the Index and time-based vesting. We calculate total stockholder return based on the one year annualized rates of return reflecting price appreciation plus reinvestment of dividends. For PSU awards granted on February 5, 2013 and on March 5, 2013, stock price appreciation is calculated based on the average closing prices of our common stock for the last 20 trading days leading to February 28, 2014. For PSU awards granted in 2011 and 2012, stock price appreciation is calculated based on the average closing prices of the applicable company's common stock for the 20 trading days ending on the last trading day of the year prior to the date of grant as compared to the average closing prices for the 20 trading days ended on the last trading day of the year of grant.
	The following table shows the percent of PSUs granted in 2011 and eligible for further time-based vesting based on our percentile placement:
	Percentile Placement of Our Total Stockholder Return		% of PSUs Eligible for Time-
			Based Vesting
	Below the 35th percentile		—%
	At least the 35th percentile, but below the 50th percentile		50%
	At least the 50th percentile, but below the 65th percentile		100%
	At least the 65th percentile, but below the 75th percentile (1)		110% to 119%
	At or above the 75th percentile		120%
	(1)               The actual percentage of PSUs eligible for further time-based vesting is based on straight-line interpolation, where, for example, if the ranking is the 70th percentile, then the vesting percentage is 115%.
	On January 17, 2012, the Compensation Committee of our Board of Directors confirmed 76.3% as the percentile rank of Omnicell’s 2011 total stockholder return. This resulted in 120% of the 2011 PSU awards, or 120,000 shares, becoming eligible for further time-based vesting. The eligible PSU awards will vest as follows: 25% of the eligible awards for the first year vested immediately on January 17, 2012 with the remaining eligible awards vesting in equal increments, semi-annually, over the subsequent three year period beginning on June 15th and December 15th of the year after the date of grant and each subsequent year. Vesting is contingent upon continued service. Of the 120,000 shares eligible for time-based vesting under the 2011 PSU awards, 10,000 shares vested during the year ended December 31, 2012.
	The following table shows the percent of PSUs granted in 2012 eligible for further time-based vesting based on our percentile placement:
	Percentile Placement of Our Total Shareholder Return	% of PSUs Eligible for Time-
		Based Vesting
	Below the 35th percentile	—%
	At least the 35th percentile, but below the 50th percentile	50%
	At least the 50th percentile	100%
	On January 22, 2013, the Compensation Committee of our Board of Directors confirmed 35.3% as the percentile rank of Omnicell's 2012 total stockholder return. This resulted in 50% of the 2012 PSU awards, or 62,500 shares, as eligible for further time-based vesting. The eligible performance-based restricted stock unit awards will vest as follows: 25% of the eligible shares vested immediately on January 22, 2013 with the remaining eligible awards vesting in equal increments, semi-annually, over the subsequent three year period beginning on June 15th and December 15th of the year after the date of grant and each subsequent year. Vesting is contingent upon continued service.
	On February 5 and March 5 2013, the Compensation Committee approved PSU awards of 125,000 shares and 12,500 shares, respectively. If the minimum performance threshold is met as determined by the Compensation Committee of the Board of Directors in 2014, the eligible performance-based restricted stock unit awards will vest as follows: 25% of the eligible shares will vest immediately, with the remaining eligible awards vesting in equal increments, semi-annually, over the subsequent three year period beginning on June 15th and December 15th of the year after the date of grant and each subsequent year. Vesting is contingent upon continued service.
	A summary of activity of the PSUs for the nine months ended September 30, 2013 is presented below:
Performance-based Stock Units	Number of Units			Weighted-
				Average
				Grant Date
				Fair Value Per
				Unit
	(in thousands)
Non-vested, December 31, 2012	175			$	11
Granted	140			$	14.74
Vested	(38	)		$	11.02
Forfeited	(24	)		$	—
Non-vested, September 30, 2013	253			$	13.07
Employee Stock Purchase Plan
We have an Employee Stock Purchase Plan (“ESPP”) under which employees can purchase shares of our common stock based on a percentage of their compensation, but not greater than 15% of their earnings, up to a maximum of $25,000 of fair value per year. The purchase price per share must be equal to the lower of 85% of the fair value of the common stock at the beginning of a 24-month offering period or the end of each six-month purchasing period. As of September 30, 2013, 4,233,557 shares had been issued under the ESPP. As of September 30, 2013 there were a total of 1,097,998 shares reserved for future issuance under the ESPP. For the three months and nine months ended September 30, 2013, 193,719 and 450,713 shares, respectively, of common stock were purchased under the ESPP.
Share-based Compensation
We account for share-based awards granted to employees and directors, including employee stock option awards, restricted stock, PSUs and RSUs issued pursuant to the 2009 Plan and employee stock purchases made under our ESPP using the estimated grant date fair value method of accounting in accordance with ASC 718, Stock Compensation. We value options and ESPP shares using the Black-Scholes-Merton option-pricing model. Restricted stock and time-based RSUs are valued at the grant date fair value of the underlying common shares. The PSUs are valued via Monte Carlo simulation, as described above.
The impact on our results for share-based compensation for the three and nine months ended September 30, 2013 and 2012 was as follows (in thousands):
	Three Months Ended September 30,						Nine Months Ended September 30,
	2013				2012		2013			2012
Cost of product and service revenues	$	325			$	275	$	955		$	776
Research and development expenses	405				232		1,019			686
Selling, general and administrative expenses	2,080				1,854		6,449			5,319
Total share-based compensation expenses	$	2,810			$	2,361	$	8,423		$	6,781

Business_Acquisition

Business Acquisition	9 Months Ended
	Sep. 30, 2013
Business Acquisition [Abstract]	'
Business Combination Disclosure [Text Block]	'
	Business Acquisition
	MTS Medication Technologies, Inc.
	On May 21, 2012, we completed our acquisition of MedPak Holdings, Inc. ("MedPak") pursuant to an Agreement and Plan of Merger (the "Merger Agreement") under which Mercury Acquisition Corp, a newly formed Omnicell subsidiary, was merged with and into MedPak, with MedPak surviving the merger as a wholly-owned subsidiary of Omnicell. MedPak is the parent company of MTS Medication Technologies, Inc. ("MTS").
	The MTS acquisition primarily was to align Omnicell with the long term trends of the healthcare market to manage the health of patients across the continuum of care. We can now better serve both the acute care and non-acute care markets. Omnicell and MTS bring capabilities to each other that strengthen the product lines and expand the medication management coverage of both companies.
	We have accounted for the transaction under the acquisition method of accounting in accordance with the provisions of FASB ASC Topic 805, Business Combinations. Under the acquisition method, the estimated fair value of the consideration transferred to purchase the acquired company is allocated to the assets acquired and the liabilities assumed based on their fair values. We have made significant estimates and assumptions in determining the allocation of the acquisition consideration.
	Pursuant to the terms of the Merger Agreement, we paid approximately $158.3 million in cash after adjustments provided for in the Merger Agreement, of which approximately $13.5 million was placed in an escrow fund, which will be distributed to MedPak's stockholders (subject to claims that we may make against the escrow fund for indemnification and other claims following the closing). The revised acquisition consideration of $158.3 million is comprised entirely of cash at closing.
	At date of acquisition, we also recorded a $1.8 million liability based on expected additional working capital adjustments. In October 2012, a portion of the escrow fund set aside for the working capital adjustment was disbursed, with Omnicell receiving $0.3 million and MedPak's former stockholders receiving the remainder. As of December 31, 2012, the working capital adjustment was reversed, with a resulting reduction in goodwill of $1.8 million and a corresponding reduction in accrued liabilities. Accounts receivable acquired were recorded at their estimated fair value, comprised of total contractual obligations due of $7.6 million, of which $0.2 million was not expected to be collected. Based on an acquisition date valuation, the preliminary estimated fair values of acquired inventory and property and equipment exceeded their historical carrying values. We recorded a preliminary step-up to the estimated fair value of acquired inventory in the amount of $1.6 million, which resulted in subsequent related charges of $1.6 million to cost of product revenues.
	In the fourth quarter of 2012, subsequent to the initial acquisition price allocation, we revised our preliminary determination of the fair value of fixed assets and intangible assets acquired from MTS, resulting in a decrease in the carrying value of acquired fixed assets of $1.3 million, and increase in the carrying value of intangibles of $0.4 million and a net increase in recorded goodwill of $0.9 million. During the first quarter of 2013, we reduced goodwill by $0.1 million due to an adjustment in stockholder's equity.
	The total revised acquisition price was approximately $158.3 million and was allocated as follows (in thousands):
		Fair value acquired
	Cash including restricted cash	$	2,000
	Accounts receivable	7,403
	Inventory	11,726
	Deferred tax assets and other current assets	2,894
	Total current assets	24,023
	Property and equipment	9,807
	Intangible assets	83,900
	Goodwill	82,800
	Other non-current assets	308
	Total assets	200,838
	Current liabilities	(7,917		)
	Non-current deferred tax liabilities	(33,386		)
	Other non-current liabilities	(1,223		)
	Net assets acquired	$	158,312
	Cash consideration, fair value	$	158,312
	Identifiable intangible assets. Acquired technology relates to MTS’ products across all of its product lines that have reached technological feasibility, primarily the OnDemand technology. Trade name is primarily related to the MTS and OnDemand brand names. Customer relationships represent existing contracted relationships with pharmacies, institutional care facilities and others. Acquired technology, customer relationships, and trade names will be amortized on a straight-line basis over their estimated useful lives, which range from 12 to 30 years.
	The estimated fair values of the acquired technology, trade names and customer relationships were primarily determined using either the relief-from-royalty or excess earnings methods. The interest rates utilized to discount net cash flows to their present values were determined after consideration of the overall enterprise rate of return and the relative risk and importance of the assets to the generation of future cash flows.
	For income tax purposes, the historical tax bases of the acquired assets and assumed liabilities, along with the tax attributes of the MTS companies, will carry over. Because the transaction was a cash-for-stock transaction, there is no tax basis in the newly acquired intangible assets. Accordingly, the acquisition accounting includes the establishment of net deferred tax liabilities of $33.4 million, resulting from book tax basis differences related to the intangible assets acquired, as well as to the step up in the value of fixed assets and inventory to their estimated fair values at the time of acquisition.
	Details of acquired intangibles are as follows (in thousands, except for years):
		Fair value acquired			Useful Life (years)	First year amortization expense
	Trade name	$	6,800		12	$	567
	Customer relationships	50,500			28 to 30	1,707
	Acquired technology	26,600			20	1,330
	Intangibles acquired	$	83,900			$	3,604
	Weighted average life of intangibles				25.14
	Goodwill. Approximately $82.8 million has been allocated to goodwill. Goodwill represents the excess of the fair value of the consideration transferred over the fair value of the underlying net tangible and identifiable intangible assets on the acquisition date. In accordance with ASC Topic 350, Intangibles - Goodwill and Other, goodwill will not be amortized, but instead will be tested for impairment at least annually or more frequently if certain indicators are present. We believe the MTS acquisition enhances our offerings and diversifies our revenue mix, providing a more robust product and service solution to our current customers while expanding our international presence. We consider these factors as supporting the amount of goodwill recorded.
	For the three and nine months ended September 30, 2013, we did not incur any acquisition-related costs in connection with the MTS acquisition. For the nine months ended September 30, 2012, we incurred approximately $3.2 million in acquisition related costs related to the MTS acquisition. These costs are included in selling, general and administrative expenses on our Condensed Consolidated Statement of Operations.

Segments

Segments	9 Months Ended
	Sep. 30, 2013
Segments [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	Segments
	Beginning with the acquisition of MTS in May, 2012, we have organized our business into two operating business segments: Acute Care, which primarily includes products and services sold to hospital customers and Non-Acute Care, which primarily includes products and services sold to customers outside of hospital settings.
	The Acute Care segment is organized around the design, manufacturing, selling and servicing of medication and supply dispensing systems. The Non-Acute Care segment includes primarily the manufacturing and selling of consumable medication blister cards, packaging equipment and ancillary products and services, but also includes medication dispensing systems sold to non-acute care pharmacies and facilities. We report segment information based on the management approach. The management approach designates the internal reporting used by the Chief Operating Decision Maker (the "CODM") for making decisions and assessing performance as the source of our operating segments. The CODM is our Chief Executive Officer. The CODM allocates resources to and assesses the performance of each operating segment, using information about its revenues, gross profit and income (loss) from operations.
	Since 1992, Omnicell has provided automation and business information solutions to acute care hospitals. We have developed product solutions that help optimize various workflows utilized in hospitals. We have also developed sophisticated sales, installation, and service capabilities to serve the specific and special needs of the acute care environment in hospitals. As the acute care market evolves, we see opportunities to provide medication adherence solutions, which were added to our product line through the acquisition of MTS. A portion of our organization structure and management processes will continue to be structured to optimize sales and service of solutions to the acute care market.
	Since 1984, MTS has provided medication adherence solutions to the non-acute care market. These solutions provide automated and semi-automated equipment to assist institutional and retail pharmacists in filling medication orders into blister cards, the primary method of medication control in non-acute care settings. Completing the product solution are the consumables used by institutional and retail pharmacists to make the medication adherence package. MTS has developed process manufacturing capabilities as well as sales capabilities to market medication adherence solutions to institutional and retail pharmacies. A portion of our organization structure and management processes will continue to be structured to optimize the product, sales, and service of solutions to the non-acute care market.
	During 2012, we realigned our management reporting structure to report sales of Omnicell's dispensing systems and other related business transactions to long-term care pharmacies and facilities. Accordingly, the operations of this portion of our activities are now being reflected as a part of the Non-Acute Care segment for three and nine months ended September 30, 2013.
	We believe that legislative changes and economic pressures to manage costs will cause healthcare organizations to manage the health of patients across the continuum of care regardless of the setting in which the care is provided. We believe we have the capabilities and market position to provide the tools needed by our customers to manage medications across the continuum of care. But we also believe that the inherent differences between medication management workflows in acute care settings and non-acute care settings will cause our product solutions and marketing strategies to be managed separately for these two customer segments.
	Effective in the second quarter of 2013, our management changed its methodology for allocating certain expenses to our reportable segments. We have reclassified segment operating results for the three and nine months ended September 30, 2012 to conform to the 2013 presentation. For the three and nine months ended September 30, 2013 and 2012, the contributions of our segments to net revenues and income from operations, and the reconciliation to total net income, were as follows (amounts in thousands):
		Three Months Ended September 30, 2013									Three Months Ended September 30, 2012
		Acute Care			Non-Acute Care			Total			Acute Care			Non-Acute Care (1)				Total
	Net revenues from external customers	$	70,640		$	23,399		$	94,039		$	64,394		19,937				$	84,331
	Cost of revenues	28,662			13,337			41,999			26,920			11,324				38,244
	Gross profit	$	41,978		$	10,062		$	52,040		$	37,474		$	8,613			$	46,087
	Gross margin %	59.4		%	43		%	55.3		%	58.2		%	43.2		%		54.7		%
	Operating expenses	32,908			8,415			41,323			29,070			5,791				34,861
	Income from operations	$	9,070		$	1,647		$	10,717		$	8,404		2,822				$	11,226
	Operating margin %	12.8		%	7		%	11.4		%	13.1		%	14.2		%		13.3		%
	Interest and other income (expense), net							25										34
	Income before provision for income taxes							10,742										11,260
	Provision for income taxes							2,987										4,340
	Net income							$	7,755									$	6,920
	(1) Non-Acute Care segment includes MTS results from May 21, 2012, the date of acquisition.
		Nine Months Ended September 30, 2013									Nine Months Ended September 30, 2012
		Acute Care			Non-Acute Care			Total			Acute Care			Non-Acute Care (1)				Total
	Net revenues from external customers	$	204,750		$	70,085		$	274,835		$	191,295		$	32,563			$	223,858
	Cost of revenues	87,784			40,276			128,060			82,859			19,787				102,646
	Gross profit	$	116,966		$	29,809		$	146,775		$	108,436		$	12,776			$	121,212
	Gross margin %	57.1		%	42.5		%	53.4		%	56.7		%	39.2		%		54.1		%
	Operating expenses	96,048			26,483			122,531			94,167			9,753				103,920
	Income from operations	$	20,918		$	3,326		$	24,244		$	14,269		3,023				$	17,292
	Operating margin %	10.2		%	4.7		%	8.8		%	7.5		%	9.3		%		7.7		%
	Interest and other income (expense), net							(134		)								57
	Income before provision for income taxes							24,110										17,349
	Provision for income taxes							6,954										6,703
	Net income							$	17,156									$	10,646
	(1) Non-Acute Care segment includes MTS results from May 21, 2012, the date of acquisition.
	At September 30, 2013, segment assets were as follows (amounts in thousands):
		30-Sep-13									31-Dec-12
		Acute Care			Non-Acute Care			Total			Acute Care			Non-Acute Care (1)				Total
	Segment Assets	$	284,067		$	221,917		$	505,984		$	235,186		$	206,633			$	441,819
	At three and nine months ended September 30, 2013 and 2012, segment depreciation/amortization, and capital expenditures were as follows (amounts in thousands):
		Three Months Ended September 30, 2013									Three Months Ended September 30, 2012
		Acute Care			Non-Acute Care			Total			Acute Care			Non-Acute Care (1)			Total
	Depreciation/Amortization	$	2,805		$	1,683		$	4,488		$	2,072		$	1,842		$	3,914
	Capital Expenditures	1,311			745			2,056			$	4,940		$	532		$	5,472
	(1) Non-Acute Care segment includes MTS results from May 21, 2012, the date of acquisition.
		Nine Months Ended September 30, 2013									Nine Months Ended September 30, 2012
		Acute Care			Non-Acute Care			Total			Acute Care			Non-Acute Care (1)			Total
	Depreciation/Amortization	$	8,351		$	5,381		$	13,732		$	6,538		$	2,709		9,247
	Capital Expenditures	3,329			4,478			7,807			$	8,947		$	612		$	9,559
	(1) Non-Acute Care segment includes MTS results from May 21, 2012, the date of acquisition.

Asset_Impairment_Notes

Asset Impairment (Notes)	9 Months Ended
	Sep. 30, 2013
Asset Impairment [Abstract]	'
Impairment of Software Development Costs [Table Text Block]	'
	Asset Impairment
	Impairment of Software Development Costs
	As part of the continuing integration of MTS, during the first quarter of 2013, we reorganized our management team, including the software development department, within the Non-Acute Care segment. Through the end of the first quarter of 2013, the Non-Acute Care segment had capitalized approximately $1.8 million of software development costs. associated with a software solution under development which was intended to assist pharmacies in manual packaging of prescriptions. In connection with our financial statement close process for the quarter ended March 31, 2013, our management reassessed the viability of this project and the net realizable value of capitalized costs in light of its decision to change the related product road map and redesign this product based on evolving market demands. As part of this redesign process, new functionality and capabilities will need to be added to the product before commercialization. This redesign is intended to provide a more robust global platform providing larger scalability and significant functionality not contained in our current beta version. As such, we have determined we can no longer support the technological feasibility of this project in conjunction with our software capitalization policy. Therefore, we charged these costs, in the amount of $1.8 million ($0.03 per diluted share, net of tax), to expense as a component of research and development in the accompanying consolidated condensed statement of operations.

Credit_Agreement_Notes

Credit Agreement (Notes)	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	Credit Agreement
	In September 2013, we entered into a credit agreement (the "Credit Agreement") with Wells Fargo Bank, National Association, as administrative agent, and the lenders from time to time party thereto. The Credit Agreement provides for a $75.0 million revolving credit facility with a $10.0 million letter of credit sub-limit. Loans under the Credit Agreement mature on September 25, 2018. The Credit Agreement permits us to request one or more increases in the aggregate commitments provided that such increases do not exceed $25.0 million in the aggregate. We expect to use the proceeds from any revolving loans under the credit facility for general corporate purposes, including future acquisitions. Our obligations under the Credit Agreement are guaranteed by certain of our domestic subsidiaries and secured by substantially all of our and the subsidiary guarantors’ assets. To date, we have not yet drawn any funds under the credit facility.
	Amounts drawn under the Credit Agreement bear interest, at our election, at a Eurodollar rate plus a margin of 1.75% per annum, or an alternate base rate equal to the highest of (a) the prime rate, (b) the federal funds rate plus 0.50%, and (c) LIBOR for an interest period of one month plus 1.75%. We are required to pay a commitment fee of 0.25% per annum on the aggregate undrawn amount of the commitments under the credit facility.
	The Credit Agreement contains customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends and other distributions. The Credit Agreement contains financial covenants that require us to, among other things, maintain a maximum consolidated total leverage ratio and a minimum consolidated fixed charge coverage ratio, in each case, as of the last day of each fiscal quarter. We were in full compliance with all covenants at September 30, 2013.

Organization_and_Summary_of_Si1

Organization and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of presentation. These interim condensed consolidated financial statements are unaudited but reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of Omnicell and its subsidiaries as of September 30, 2013, the results of their operations and comprehensive income for the three and nine months ended September 30, 2013 and 2012 and their cash flows for the nine months ended September 30, 2013 and 2012. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2012.
	Our results of operations, comprehensive income and cash flows for the three and nine months ended September 30, 2013 are not necessarily indicative of results that may be expected for the year ending December 31, 2013, or for any future period.
Use of Estimates, Policy [Policy Text Block]	'
	Use of estimates. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, share-based compensation, inventory valuation, valuation of goodwill and purchased intangibles, valuation of long-lived assets and accounting for income taxes.
Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]	'
	Principles of consolidation. The condensed consolidated financial statements include the accounts of our wholly-owned subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation
Foreign Currency Transactions and Translations Policy [Policy Text Block]	'
	Foreign currency translation. We translate the assets and liabilities of our non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Revenue and expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recorded as foreign currency translation adjustments and included in accumulated other comprehensive income in stockholders’ equity.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair value of financial instruments. We value our financial assets and liabilities on a recurring basis using the fair value hierarchy established in Accounting Standards Codification ("ASC") 820, Fair Value Measurements and Disclosures. ASC 820 describes three levels of inputs that may be used to measure fair value, as follows:
	Level 1 inputs, which include quoted prices in active markets for identical assets or liabilities;
	Level 2 inputs, which include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and
	Level 3 inputs, which include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management judgment or estimation.
	At September 30, 2013 and December 31, 2012, our financial assets, measured at fair value on a recurring basis, utilizing Level 1 inputs included money market funds, classified as cash equivalents. For these items, quoted market prices are readily available and fair value approximates carrying value. We do not currently have any material financial instruments, measured at fair value on a recurring basis, utilizing Level 2 or Level 3 inputs
Marketable Securities, Policy [Policy Text Block]	'
	Classification of marketable securities. Securities held as investments for the indefinite future, pending future spending requirements, are classified as “Available-for-sale” and are carried at their fair value, with any unrealized gain or loss recorded to other comprehensive income until realized. At September 30, 2013 and December 31, 2012, we held $64.8 million and $38.9 million, respectively, of money market mutual funds classified as available-for-sale cash equivalents. We do not hold securities for purposes of trading.
Derivative Instruments and Hedging Activities Disclosure [Text Block]	'
	Currency forward contracts. From time to time we enter into foreign currency forward contracts to protect our business from the risk that exchange rates may affect the eventual cash flows resulting from intercompany transactions between Omnicell and our foreign subsidiaries. These transactions primarily arise as a result of products manufactured in the U.S. and sold to foreign subsidiaries in U.S. dollars rather than the subsidiaries' functional currencies. These forward contracts are considered to be financial derivative instruments and are recorded at fair value in the balance sheet. Changes in fair value of these financial derivative instruments are either recognized in other comprehensive income (a component of stockholders' equity) or net income depending on whether the derivative has been designated and qualifies as a highly effective hedging instrument. At September 30, 2013 and December 31, 2012, we had no foreign currency forward contracts which qualify for hedge accounting.
Segment Reporting, Policy [Policy Text Block]	'
	Segment information. Prior to the acquisition of MTS, we managed our business on the basis of a single operating segment, and a single reporting unit within that segment in accordance with ASC 280, Segment Reporting. Beginning with the acquisition of MTS in May 2012, we have organized our business into two operating business segments: Acute Care, which includes primarily products and services sold to hospital customers, and Non-Acute Care, which includes primarily products and services sold to customers outside of the hospital setting.
	The Acute Care segment is organized around the design, manufacturing, selling and servicing of medication and supply dispensing systems. The Non-Acute Care segment includes primarily the manufacturing and selling of consumable medication blister cards, packaging equipment and ancillary products and services, but also includes medication dispensing systems sold to non-acute care pharmacies and facilities. We report segment information based on the management approach. The management approach designates the internal reporting used by the Chief Operating Decision Maker (the "CODM") for making decisions and assessing performance as the source of our operating segments. The CODM is our Chief Executive Officer. The CODM allocates resources to and assesses the performance of each operating segment, using information about its revenues, gross profit and income (loss) from operations.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue recognition. We earn revenues from sales of our medication control systems together with related consumables and services, and medical/surgical supply control systems with related services, which are sold in our principal market, which is the healthcare industry. Revenues related to consumable products are reported net of discounts provided to our customers. Our customer arrangements typically include one or more of the following deliverables:
	•	Products—Software-enabled equipment that manages and regulates the storage and dispensing of pharmaceuticals, consumable blister cards and packaging equipment and other medical supplies.
	•	Software—Additional software applications that enable incremental functionality of our equipment.
	•	Installation—Installation of equipment as integrated systems at customers' sites.
	•	Post-installation technical support—Phone support, on-site service, parts and access to unspecified software upgrades and enhancements, if and when available.
	•	Professional services—Other customer services such as training and consulting.
	We recognize revenue when the earnings process is complete, based upon our evaluation of whether the following four criteria have been met:
	•	Persuasive evidence of an arrangement exists. We use signed customer contracts and signed customer purchase orders as evidence of an arrangement for equipment leases and sales. For service engagements, we use a signed services agreement and a statement of work to evidence an arrangement.
	•	Delivery has occurred. Equipment and software product delivery is deemed to occur upon successful installation and receipt of a signed and dated customer confirmation of installation letter, providing evidence that we have delivered what a customer ordered. In instances of a customer self-installed installation, product delivery is deemed to have occurred upon receipt of a signed and dated customer confirmation letter. If a sale does not require installation, we recognize revenue on delivery of products to the customer, including transfer of title and risk of loss, assuming all other revenue criteria are met. We recognize revenue from sales of products to distributors upon delivery, when no contractual obligations for installation exists, assuming all other revenue criteria are met since we do not allow for rights of return or refund. For sales to distributors where we assume contractual installation obligations or new distributors whom we have not fully trained to install our products, the equipment and software product delivery is deemed to occur upon successful installation and receipt of a signed and dated customer confirmation of installation letter. For the sale of consumable blister cards, we recognize revenue when title and risk of loss of the products shipped have transferred to the customer, which usually occurs upon shipment from our facilities. Assuming all other revenue criteria are met, we recognize revenue for support services ratably over the related support services contract period, and we recognize revenue on training and professional services as those services are performed.
	•	Fee is fixed or determinable. We assess whether a fee is fixed or determinable at the outset of the arrangement based on the payment terms associated with the transaction. We have established a history of collecting under the original contract without providing concessions on payments, products or services.
	•	Collection is probable. We assess the probability of collecting from each customer at the outset of the arrangement based on a number of factors, including the customer's payment history and its current creditworthiness. If, in our judgment, collection of a fee is not probable, we defer the revenue until the uncertainty is removed, which generally means revenue is recognized upon our receipt of cash payment assuming all other revenue criteria are met. Our historical experience has been that collection from our customers is generally probable.
	In arrangements with multiple deliverables, assuming all other revenue criteria are met, we recognize revenue for individual delivered items if they have value to the customer on a standalone basis. We allocate arrangement consideration at the inception of the arrangement to all deliverables using the relative selling price method. This method requires us to determine the selling price at which each deliverable could be sold if it were sold regularly on a standalone basis. When available, we use vendor-specific objective evidence ("VSOE") of fair value as the selling price. VSOE represents the price charged for a deliverable when it is sold separately or for a deliverable not yet being sold separately, the price established by management with the relevant authority. We consider VSOE to exist when approximately 80% or more of our standalone sales of an item are priced within a reasonably narrow pricing range (plus or minus 15% of the median rates). We have established VSOE of fair value for our post-installation technical support services and professional services. When VSOE of fair value is not available, third-party evidence ("TPE") of fair value for similar products and services is acceptable; however, our offerings and market strategy differ from those of our competitors, such that we cannot obtain sufficient comparable information about third parties' prices. If neither VSOE nor TPE are available, we use our best estimates of selling prices ("BESP"). We determine BESP considering factors such as market conditions, sales channels, internal costs and product margin objectives and pricing practices. We regularly review and update our VSOE, TPE and BESP information and obtain formal approval by appropriate levels of management.
	The relative selling price method allocates total arrangement consideration proportionally to each deliverable on the basis of its estimated selling price. In addition, the amount recognized for any delivered items cannot exceed that which is not contingent upon delivery of any remaining items in the arrangement.
	We also use the residual method of allocating the arrangement consideration in certain circumstances. We use the residual method to allocate total arrangement consideration between delivered and undelivered items for any arrangements entered into prior to January 1, 2011 and not subsequently materially-modified. The use of the residual method is required by software revenue recognition rules that applied to sales of most of our products and services until the adoption of the new revenue recognition guidance. We also use the residual method to allocate revenue between the software products that enable incremental equipment functionality and thus are not deemed to deliver its essential functionality, and the related post-installation technical support, as these products and services continue to be accounted for under software revenue recognition rules. Under the residual method, the amount allocated to the undelivered elements equals VSOE of fair value of these elements. Any remaining amounts are attributed to the delivered items and are recognized when those items are delivered.
	A portion of our sales are made through multi-year lease agreements. Under sales-type leases, we recognize revenue for our hardware and software products net of lease execution costs, such as post-installation product maintenance and technical support, at the net present value of the lease payment stream once our installation obligations have been met. We optimize cash flows by selling a majority of our non-U.S. government leases to third-party leasing finance companies on a non-recourse basis. We have no obligation to the leasing company once the lease has been sold. Some of our sales-type leases, mostly those relating to U.S. government hospitals, are retained in-house. Interest income in these leases is recognized in product revenue using the effective interest method.
Receivables, Policy [Policy Text Block]	'
	Accounts receivable and notes receivable (net investment in sales type leases). We actively manage our accounts receivable to minimize credit risk. We typically sell to customers for which there is a history of successful collection. New customers are subject to a credit review process, which evaluates that customer's financial position and ability to pay. We continually monitor and evaluate the collectability of our trade receivables based on a combination of factors. We record specific allowances for doubtful accounts when we become aware of a specific customer's impaired ability to meet its financial obligation to us, such as in the case of bankruptcy filings or deterioration of financial position. Uncollectible amounts are charged off against trade receivables and the allowance for doubtful accounts when we make a final determination that there is no reasonable expectation of recovery. Estimates are used in determining our allowances for all other customers based on factors such as current trends, the length of time the receivables are past due and historical collection experience. While we believe that our allowance for doubtful accounts receivable is adequate and that the judgment applied is appropriate, such estimated amounts could differ materially from what will actually be uncollectible in the future.
	The retained in-house leases discussed above are considered financing receivables. Our credit policies and evaluation of credit risk and write-off policies are applied alike to trade receivables and the net-investment in sales-type leases. For both, an account is generally past due after thirty days. The financing receivables also have customer-specific reserves for accounts identified for specific impairment and a non-specific reserve applied to the remaining population, based on factors such as current trends, the length of time the receivables are past due and historical collection experience. The retained in-house leases are not stratified by portfolio or class. Financing receivables which are reserved are generally transferred to cash-basis accounting so that revenue is recognized only as cash is received. However, the cash basis accounts continue to accrue interest.
Transfers and Servicing of Financial Assets, Transfers of Financial Assets, Sales, Policy [Policy Text Block]	'
	Sales of accounts receivable. We record the sale of our accounts receivables as “true sales” in accordance with accounting guidance for transfers and servicing of financial assets. During the three months ended September 30, 2013 and 2012, we transferred non-recourse accounts receivable totaling $7.2 million and $14.6 million, respectively, which approximated fair value, to third-party leasing companies. During the nine months ended September 30, 2013 and 2012, we transferred non-recourse accounts receivable totaling $28.1 million and $42.5 million, respectively, which approximated fair value, to third-party leasing companies. At September 30, 2013 and December 31, 2012, accounts receivable included $0.5 million and $0.7 million, respectively, due from third-party leasing companies for transferred non-recourse accounts receivable.
Shipping and Handling Cost, Policy [Policy Text Block]	'
	Accounting policy for shipping costs. Outbound freight billed to customers is recorded as product revenue. The related shipping and handling cost is expensed as part of selling, general and administrative expense.
Income Tax, Policy [Policy Text Block]	'
	Income taxes. We record an income tax provision for the anticipated tax consequences of the reported results of operations. In accordance with GAAP, the provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply in the periods in which those tax assets and liabilities are expected to be realized. In the event that we determine all or part of the net deferred tax assets are not realizable in the future, we will record a valuation allowance that would be charged to earnings in the period such determination is made.
	In accordance with ASC 740, Tax Provisions, we recognize the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The calculation of tax liabilities involves significant judgment in estimating the impact of uncertainties in the application of GAAP and complex tax laws. Resolution of these uncertainties in a manner inconsistent with management’s expectations could have a material impact on our financial condition and operating results.
	We provide for income taxes for each interim period based on the estimated annual effective tax rate for the year, adjusting for discrete items in the quarter in which they arise. The annual effective tax rate before discrete items was 38.1% and 41.5% for the nine months ended September 30, 2013 and 2012, respectively. The 2013 annual effective tax rate differed from the statutory rate of 35.0% primarily due to the unfavorable impact of state income taxes, non-deductible equity charges, and other non-deductible expenditures, which were partially offset by the federal research and development credit claimed and the domestic production activities deduction.
	The 2012 annual effective tax rate differed from the statutory rate of 35.0% primarily due to the unfavorable impact of state income taxes, non-deductible equity charges, and other non-deductible expenditures, which were partially offset by the domestic production activities deduction.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recently Adopted Accounting Standards
	In February 2013, the Financial Accounting Standards Board ("FASB") issued ASU 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (AOCI), which aims to improve the reporting of reclassifications out of AOCI. This update requires an entity to report the effect of significant reclassifications out of AOCI on the respective line items in net income if the amount being reclassified is required under GAAP to be reclassified in its entirety to net income. For other amounts that are not required under GAAP to be reclassified in their entirety to net income in the same reporting period, an entity is required to cross-reference other disclosures required under GAAP that provide additional detail about those amounts. The amendments do not change the current requirements for reporting net income or other comprehensive income in financial statements. For public entities, the amendments are effective prospectively for reporting periods beginning after December 15, 2012. We adopted this guidance in the first quarter of 2013. This update did not have any significant impact on our financial position, operating results or cash flows.
Earnings Per Share, Policy [Policy Text Block]	'
	t income per share is computed by dividing net income for the period by the weighted average number of shares outstanding during the period, less shares subject to repurchase. Diluted net income per share is computed by dividing net income for the period by the weighted average number of shares, less shares subject to repurchase, plus, if dilutive, potential common stock outstanding during the period. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards and restricted stock units computed using the treasury stock method. Since t
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	We account for share-based awards granted to employees and directors, including employee stock option awards, restricted stock, PSUs and RSUs issued pursuant to the 2009 Plan and employee stock purchases made under our ESPP using the estimated grant date fair value method of accounting in accordance with ASC 718, Stock Compensation. We value options and ESPP shares using the Black-Scholes-Merton option-pricing model. Restricted stock and time-based RSUs are valued at the grant date fair value of the underlying common shares. The PSUs are valued via Monte Carlo simulation, as described above.

Net_Income_Per_Share_Tables

Net Income Per Share (Tables)	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	The calculation of basic and diluted net income per share is as follows (in thousands, except per share amounts):
		Three Months Ended September 30,				Nine Months Ended September 30,
		2013		2012		2013		2012
	Basic:
	Net income	$	7,755	$	6,920	$	17,156	$	10,646
	Weighted average shares outstanding — basic	35,133		33,193		34,499		33,316
	Net income per share — basic	$	0.22	$	0.21	$	0.5	$	0.32
	Diluted:
	Net income	$	7,755	$	6,920	$	17,156	$	10,646
	Weighted average shares outstanding — basic	35,133		33,193		34,499		33,316
	Add: Dilutive effect of employee stock plans	1,057		875		967		925
	Weighted average shares outstanding — diluted	36,190		34,068		35,466		34,241
	Net income per share — diluted	$	0.21	$	0.2	$	0.48	$	0.31

Cash_and_Cash_Equivalents_Shor1

Cash and Cash Equivalents, Short-term Investments and Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2013
Cash and Cash Equivalents [Abstract]	'
Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]	'
	Cash and cash equivalents consist of the following significant investment asset classes, with disclosure of amortized cost, gross unrealized gains and losses and fair value as of September 30, 2013 and December 31, 2012 (in thousands):
		30-Sep-13
		Amortized		Unrealized		Unrealized		Fair Value		Cash / Cash		Security
		Cost		Gains		Losses				Equivalents		Classification
	Cash	$	51,415	$	—	$	—	$	51,415	$	51,415	N/A
	Money market fund	64,775		—		—		64,775		64,775		Available for sale
	Total cash and cash equivalents	$	116,190	$	—	$	—	$	116,190	$	116,190
	c	31-Dec-12
		Amortized		Unrealized		Unrealized		Fair Value		Cash / Cash		Security
		Cost		Gains		Losses				Equivalents		Classification
	Cash	$	23,422	$	—	$	—	$	23,422	$	23,422	N/A
	Money market fund	38,892		—		1		38,891		38,891		Available for sale
	Total cash and cash equivalents	$	62,314	$	—	$	1	$	62,313	$	62,313
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	'
		Quoted Prices in Active		Significant Other		Significant		Total Fair
		Markets for Identical		Observable Inputs		Unobservable		Value
		Instruments		(Level 2)		Inputs
		(Level 1)				(Level 3)
	At September 30, 2013
	Money market fund	$	64,775	$	—	$	—	$	64,775
	Total	$	64,775	$	—	$	—	$	64,775
	At December 31, 2012
	Money market fund	$	38,891	$	—	$	—	$	38,891
	Total	$	38,891	$	—	$	—	$	38,891

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2012
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
	Inventories consist of the following (in thousands):
		September 30,		December 31,
		2013		2012
	Raw materials	$	11,120	$	9,994
	Work in process	963		385
	Finished goods	18,622		16,524
	Total	$	30,705	$	26,903

Property_and_Equipment_Tables

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property and equipment consist of the following (in thousands):
		September 30,			December 31,
		2013			2012
	Equipment	$	35,483		$	32,528
	Furniture and fixtures	5,149			5,126
	Leasehold improvements	7,356			6,992
	Purchased software	19,800			19,870
	Capital in process	3,491			2,693
		71,279			67,209
	Accumulated depreciation and amortization	(37,787		)	(33,102		)
	Property and equipment, net	$	33,492		$	34,107

Net_Investment_in_SalesType_Le1

Net Investment in Sales-Type Leases (Tables)	9 Months Ended
	Sep. 30, 2013
Capital Leases, Net Investment in Sales Type Leases [Abstract]	'
sales type lease investment [Table Text Block]	'
	Our sales-type leases are for terms generally up to five years. Sales-type lease receivables are collateralized by the underlying equipment. The components of our net investment in sales-type leases are as follows (in thousands):
		September 30,			December 31,
		2013			2012
	Net minimum lease payments to be received	$	18,788		$	19,665
	Less unearned interest income portion	1,157			1,205
	Net investment in sales-type leases	17,631			18,460
	Less current portion(1)	5,233			5,232
	Non-current net investment in sales-type leases(2)	$	12,398		$	13,228
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	'
	The minimum lease payments under sales-type leases as of September 30, 2013 were as follows (in thousands):
	2013 (remaining three months)	$	1,640
	2014	5,495
	2015	4,536
	2016	3,341
	2017	2,603
	Thereafter	1,173
	Total	$	18,788
Allowance for Credit Losses on Financing Receivables [Table Text Block]	'
	The following table summarizes the credit losses and recorded investment in sales-type leases, excluding unearned interest (in thousands):
		Allowance for Credit Losses			Recorded Investment				Recorded Investment
					in Sales-type Leases Gross				in Sales-type Leases Net
	Credit loss disclosure for September 30, 2013:
	Accounts individually evaluated for impairment	$	22		$	22			$	—
	Accounts collectively evaluated for impairment	152			17,783				17,631
	Ending balances: September 30, 2013	$	174		$	17,805			$	17,631
	Credit loss disclosure for December 31, 2012:
	Accounts individually evaluated for impairment	$	489		$	489			$	—
	Accounts collectively evaluated for impairment	118			18,578				18,460
	Ending balances: December 31, 2012	$	607		$	19,067			$	18,460
Schedule of Credit Losses Related to Financing Receivables, Noncurrent [Table Text Block]	'
	The following table summarizes the activity for the allowance for credit losses for the investment in sales-type leases for the three and nine months ended September 30, 2013 and 2012 (in thousands):
		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2012			2013			2012
	Allowance for credit losses, beginning of period	$	184		$	659		$	607		$	284
	Current period provision	15			4			34			426
	Direct write-downs charged against the allowance	—			—			(413		)	—
	Recoveries of amounts previously charged off	(25		)	(26		)	(54		)	(73		)
	Allowance for credit losses, end of period	$	174		$	637		$	174		$	637

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Goodwill [Table Text Block]	'
		Goodwill at December 31, 2012		Adjustments to Goodwill			Goodwill at September 30, 2013
	Reporting units:
	Acute Care	$	28,543	$	—		$	28,543
	Non-Acute Care	82,864		(64		)	82,800
	Total	$	111,407	$	(64	)	$	111,343
	Goodwill acquired reflects the May 21, 2012 acquisition of MedPak by Omnicell. MedPak is the parent company of MTS, a worldwide provider of medication adherence packaging systems. The acquired goodwill was assigned to our new reporting unit called Non-Acute Care, created as a result of the MTS acquisition. During the first quarter of 2013, we reduced goodwill by approximately $0.1 million due to the adjustment to the fair value of an acquired foreign currency forward contract previously carried in a component of stockholder's equity.
	There were no indefin
Schedule of Intangible Assets and Goodwill [Table Text Block]	'
	There were no indefinite-life intangibles at either September 30, 2013 or December 31, 2012. Finite-life intangible assets consist of the following (in thousands):
		September 30, 2013							December 31, 2012
		Gross					Net		Gross				Net
		Carrying		Accumulated			Carrying		Carrying		Accumulated		Carrying		Amortization
		Amount		Amortization			Amount		Amount		Amortization		Amount		Life
	Finite-lived intangibles:
	Customer relationships	$	54,730	$	4,698		$	50,032	$	54,730	$	3,081	$	51,649	5-30 years
	Acquired technology	27,580		2,230			25,350		27,580		1,128		26,452		3-20 years
	Patents	1,363		244			1,119		1,217		259		958		20 years
	Trade name	6,890		861			6,029		6,890		414		6,476		3-12 years
	Non-compete agreements	60		60			—		60		45		15		3 years
	Total finite-lived intangibles	$	90,623	$	8,093		$	82,530	$	90,477	$	4,927	$	85,550
	Amortization expense totaled $1.1 million and $1.1 million for the three months ended September 30, 2013 and 2012, respectively. Amortization expense totaled $3.2 million and $1.8 million for the nine months ended September 30, 2013 and 2012, respectively. The amortization of acquired technology is included within product cost of sales; other acquired intangibles are usually amortized within selling, general and administrative expenses.
	Esti
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	Estimated annual expected amortization expense of the finite-lived intangible assets at September 30, 2013 was as follows (in thousands):
	2013 (remaining three months)	$	1,059
	2014	4,229
	2015	4,204
	2016	3,854
	2017	3,818
	2018	3,711
	Thereafter	61,655
	Total	$	82,530

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2013
Accrued Liabilities, Current [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	Accrued liabilities consist of the following (in thousands):
		September 30,		December 31,
		2013		2012
	Rebates and lease buyouts	$	3,379	$	3,179
	Advance payments from customers	4,272		2,829
	Accrued Group Purchasing Organization (GPO) fees	2,492		2,278
	Technology license purchase obligation, current portion	1,500		1,750
	Taxes payable (receivable)	774		555
	Other	1,602		1,397
	Total	$	14,019	$	11,988

Deferred_Gross_Profit_Tables

Deferred Gross Profit (Tables)	9 Months Ended
	Sep. 30, 2013
Deferred Gross Profit [Abstract]	'
Deferred Gross Profit [Table Text Block]	'
	Deferred gross profit consists of the following (in thousands):
		September 30,			December 31,
		2013			2012
	Sales of medication and supply dispensing systems and packaging equipment, which have been delivered and invoiced but not yet installed	$	40,919		$	30,138
	Cost of revenues, excluding installation costs	(15,713		)	(9,366		)
	Deferred gross profit	$	25,206		$	20,772

Commitments_Tables

Commitments (Tables)	9 Months Ended
	Sep. 30, 2013
Commitments [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	At September 30, 2013, the minimum payments under our operating leases for each of the five succeeding fiscal years were as follows (in thousands):
	2013 (remaining three months)	$	1,462
	2014	5,722
	2015	5,476
	2016	5,150
	2017	4,468
	2018	4,298
	Thereafter	16,600
	Total	$	43,176

Stock_Option_Plans_and_ShareBa1

Stock Option Plans and Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Stock Option Plans and Share-Based Compensation [Abstract]	'
PSU % eligible vesting vs Total Shareholder Return - Second year [Table Text Block]	'
	The following table shows the percent of PSUs granted in 2012 eligible for further time-based vesting based on our percentile placement:
	Percentile Placement of Our Total Shareholder Return	% of PSUs Eligible for Time-
		Based Vesting
	Below the 35th percentile	—%
	At least the 35th percentile, but below the 50th percentile	50%
	At least the 50th percentile	100%
Schedule of Stock Options Roll Forward [Table Text Block]	'
	A summary of aggregate option activity for the nine months ended September 30, 2013 is presented below:
	Options:		Number of Shares			Weighted-
						Average
						Exercise Price
			(in thousands)
	Outstanding at December 31, 2012		4,470			$	14.06
	Granted		296			$	18.1
	Exercised		(1,450	)		$	12.59
	Forfeited		(75	)		$	14.4
	Expired		(56	)		$	15.68
	Outstanding at September 30, 2013		3,185			$	15.07
	Exercisable at September 30, 2013		2,186			$	14.85
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	'
	A summary of activity of both restricted stock and RSUs for the nine months ended September 30, 2013 is presented below:
		Restricted Stock						Restricted Stock Units
		Number of			Weighted-Average			Number of		Weighted-Average
		Shares			Grant Date			Shares		Grant Date
					Fair Value Per					Fair Value Per
					Share					Share
		(in thousands)						(in thousands)
	Non-vested, December 31, 2012	58			$	14.19		389		$	14.09
	Granted	55			$	18.2		125		$	18.12
	Vested	(61	)		$	14.23		(98	)	$	13.9
	Forfeited	—			$	—		(21	)	$	14.07
	Non-vested, September 30, 2013	52			$	18.43		395		$	15.41
PSU % eligible vesting vs total Shareholder Return placement - First year [Table Text Block]	'
	A summary of activity of the PSUs for the nine months ended September 30, 2013 is presented below:
	Performance-based Stock Units	Number of Units			Weighted-
					Average
					Grant Date
					Fair Value Per
					Unit
		(in thousands)
	Non-vested, December 31, 2012	175			$	11
	Granted	140			$	14.74
	Vested	(38	)		$	11.02
	Forfeited	(24	)		$	—
	Non-vested, September 30, 2013	253			$	13.07
	The following table shows the percent of PSUs granted in 2011 and eligible for further time-based vesting based on our percentile placement:
	Percentile Placement of Our Total Stockholder Return		% of PSUs Eligible for Time-
			Based Vesting
	Below the 35th percentile		—%
	At least the 35th percentile, but below the 50th percentile		50%
	At least the 50th percentile, but below the 65th percentile		100%
	At least the 65th percentile, but below the 75th percentile (1)		110% to 119%
	At or above the 75th percentile		120%
	(1)               The actual percentage of PSUs eligible for further time-based vesting is based on straight-line interpolation, where, for example, if the ranking is the 70th percentile, then the vesting percentage is 115%.
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
	The impact on our results for share-based compensation for the three and nine months ended September 30, 2013 and 2012 was as follows (in thousands):

Segments_Tables

Segments (Tables)	9 Months Ended
	Sep. 30, 2013
Segment Reporting Information [Line Items]	'
Segment Reporting Disclosure [Text Block]	'
	Segments
	Beginning with the acquisition of MTS in May, 2012, we have organized our business into two operating business segments: Acute Care, which primarily includes products and services sold to hospital customers and Non-Acute Care, which primarily includes products and services sold to customers outside of hospital settings.
	The Acute Care segment is organized around the design, manufacturing, selling and servicing of medication and supply dispensing systems. The Non-Acute Care segment includes primarily the manufacturing and selling of consumable medication blister cards, packaging equipment and ancillary products and services, but also includes medication dispensing systems sold to non-acute care pharmacies and facilities. We report segment information based on the management approach. The management approach designates the internal reporting used by the Chief Operating Decision Maker (the "CODM") for making decisions and assessing performance as the source of our operating segments. The CODM is our Chief Executive Officer. The CODM allocates resources to and assesses the performance of each operating segment, using information about its revenues, gross profit and income (loss) from operations.
	Since 1992, Omnicell has provided automation and business information solutions to acute care hospitals. We have developed product solutions that help optimize various workflows utilized in hospitals. We have also developed sophisticated sales, installation, and service capabilities to serve the specific and special needs of the acute care environment in hospitals. As the acute care market evolves, we see opportunities to provide medication adherence solutions, which were added to our product line through the acquisition of MTS. A portion of our organization structure and management processes will continue to be structured to optimize sales and service of solutions to the acute care market.
	Since 1984, MTS has provided medication adherence solutions to the non-acute care market. These solutions provide automated and semi-automated equipment to assist institutional and retail pharmacists in filling medication orders into blister cards, the primary method of medication control in non-acute care settings. Completing the product solution are the consumables used by institutional and retail pharmacists to make the medication adherence package. MTS has developed process manufacturing capabilities as well as sales capabilities to market medication adherence solutions to institutional and retail pharmacies. A portion of our organization structure and management processes will continue to be structured to optimize the product, sales, and service of solutions to the non-acute care market.
	During 2012, we realigned our management reporting structure to report sales of Omnicell's dispensing systems and other related business transactions to long-term care pharmacies and facilities. Accordingly, the operations of this portion of our activities are now being reflected as a part of the Non-Acute Care segment for three and nine months ended September 30, 2013.
	We believe that legislative changes and economic pressures to manage costs will cause healthcare organizations to manage the health of patients across the continuum of care regardless of the setting in which the care is provided. We believe we have the capabilities and market position to provide the tools needed by our customers to manage medications across the continuum of care. But we also believe that the inherent differences between medication management workflows in acute care settings and non-acute care settings will cause our product solutions and marketing strategies to be managed separately for these two customer segments.
	Effective in the second quarter of 2013, our management changed its methodology for allocating certain expenses to our reportable segments. We have reclassified segment operating results for the three and nine months ended September 30, 2012 to conform to the 2013 presentation. For the three and nine months ended September 30, 2013 and 2012, the contributions of our segments to net revenues and income from operations, and the reconciliation to total net income, were as follows (amounts in thousands):
		Three Months Ended September 30, 2013									Three Months Ended September 30, 2012
		Acute Care			Non-Acute Care			Total			Acute Care			Non-Acute Care (1)				Total
	Net revenues from external customers	$	70,640		$	23,399		$	94,039		$	64,394		19,937				$	84,331
	Cost of revenues	28,662			13,337			41,999			26,920			11,324				38,244
	Gross profit	$	41,978		$	10,062		$	52,040		$	37,474		$	8,613			$	46,087
	Gross margin %	59.4		%	43		%	55.3		%	58.2		%	43.2		%		54.7		%
	Operating expenses	32,908			8,415			41,323			29,070			5,791				34,861
	Income from operations	$	9,070		$	1,647		$	10,717		$	8,404		2,822				$	11,226
	Operating margin %	12.8		%	7		%	11.4		%	13.1		%	14.2		%		13.3		%
	Interest and other income (expense), net							25										34
	Income before provision for income taxes							10,742										11,260
	Provision for income taxes							2,987										4,340
	Net income							$	7,755									$	6,920
	(1) Non-Acute Care segment includes MTS results from May 21, 2012, the date of acquisition.
		Nine Months Ended September 30, 2013									Nine Months Ended September 30, 2012
		Acute Care			Non-Acute Care			Total			Acute Care			Non-Acute Care (1)				Total
	Net revenues from external customers	$	204,750		$	70,085		$	274,835		$	191,295		$	32,563			$	223,858
	Cost of revenues	87,784			40,276			128,060			82,859			19,787				102,646
	Gross profit	$	116,966		$	29,809		$	146,775		$	108,436		$	12,776			$	121,212
	Gross margin %	57.1		%	42.5		%	53.4		%	56.7		%	39.2		%		54.1		%
	Operating expenses	96,048			26,483			122,531			94,167			9,753				103,920
	Income from operations	$	20,918		$	3,326		$	24,244		$	14,269		3,023				$	17,292
	Operating margin %	10.2		%	4.7		%	8.8		%	7.5		%	9.3		%		7.7		%
	Interest and other income (expense), net							(134		)								57
	Income before provision for income taxes							24,110										17,349
	Provision for income taxes							6,954										6,703
	Net income							$	17,156									$	10,646
	(1) Non-Acute Care segment includes MTS results from May 21, 2012, the date of acquisition.
	At September 30, 2013, segment assets were as follows (amounts in thousands):
		30-Sep-13									31-Dec-12
		Acute Care			Non-Acute Care			Total			Acute Care			Non-Acute Care (1)				Total
	Segment Assets	$	284,067		$	221,917		$	505,984		$	235,186		$	206,633			$	441,819
	At three and nine months ended September 30, 2013 and 2012, segment depreciation/amortization, and capital expenditures were as follows (amounts in thousands):
		Three Months Ended September 30, 2013									Three Months Ended September 30, 2012
		Acute Care			Non-Acute Care			Total			Acute Care			Non-Acute Care (1)			Total
	Depreciation/Amortization	$	2,805		$	1,683		$	4,488		$	2,072		$	1,842		$	3,914
	Capital Expenditures	1,311			745			2,056			$	4,940		$	532		$	5,472
	(1) Non-Acute Care segment includes MTS results from May 21, 2012, the date of acquisition.
		Nine Months Ended September 30, 2013									Nine Months Ended September 30, 2012
		Acute Care			Non-Acute Care			Total			Acute Care			Non-Acute Care (1)			Total
	Depreciation/Amortization	$	8,351		$	5,381		$	13,732		$	6,538		$	2,709		9,247
	Capital Expenditures	3,329			4,478			7,807			$	8,947		$	612		$	9,559
	(1) Non-Acute Care segment includes MTS results from May 21, 2012, the date of acquisition.
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	'
	For the three and nine months ended September 30, 2013 and 2012, the contributions of our segments to net revenues and income from operations, and the reconciliation to total net income, were as follows (amounts in thousands):
		Three Months Ended September 30, 2013									Three Months Ended September 30, 2012
		Acute Care			Non-Acute Care			Total			Acute Care			Non-Acute Care (1)				Total
	Net revenues from external customers	$	70,640		$	23,399		$	94,039		$	64,394		19,937				$	84,331
	Cost of revenues	28,662			13,337			41,999			26,920			11,324				38,244
	Gross profit	$	41,978		$	10,062		$	52,040		$	37,474		$	8,613			$	46,087
	Gross margin %	59.4		%	43		%	55.3		%	58.2		%	43.2		%		54.7		%
	Operating expenses	32,908			8,415			41,323			29,070			5,791				34,861
	Income from operations	$	9,070		$	1,647		$	10,717		$	8,404		2,822				$	11,226
	Operating margin %	12.8		%	7		%	11.4		%	13.1		%	14.2		%		13.3		%
	Interest and other income (expense), net							25										34
	Income before provision for income taxes							10,742										11,260
	Provision for income taxes							2,987										4,340
	Net income							$	7,755									$	6,920
	(1) Non-Acute Care segment includes MTS results from May 21, 2012, the date of acquisition.
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	At September 30, 2013, segment assets were as follows (amounts in thousands):
		30-Sep-13									31-Dec-12
		Acute Care			Non-Acute Care			Total			Acute Care			Non-Acute Care (1)				Total
	Segment Assets	$	284,067		$	221,917		$	505,984		$	235,186		$	206,633			$	441,819
	At three and nine months ended September 30, 2013 and 2012, segment depreciation/amortization, and capital expenditures were as follows (amounts in thousands):
		Three Months Ended September 30, 2013									Three Months Ended September 30, 2012
		Acute Care			Non-Acute Care			Total			Acute Care			Non-Acute Care (1)			Total
	Depreciation/Amortization	$	2,805		$	1,683		$	4,488		$	2,072		$	1,842		$	3,914
	Capital Expenditures	1,311			745			2,056			$	4,940		$	532		$	5,472
	(1) Non-Acute Care segment includes MTS results from May 21, 2012, the date of acquisition.
		Nine Months Ended September 30, 2013									Nine Months Ended September 30, 2012
		Acute Care			Non-Acute Care			Total			Acute Care			Non-Acute Care (1)			Total
	Depreciation/Amortization	$	8,351		$	5,381		$	13,732		$	6,538		$	2,709		9,247
	Capital Expenditures	3,329			4,478			7,807			$	8,947		$	612		$	9,559
	(1) Non-Acute Care segment includes MTS results from May 21, 2012, the date of acquisition.

Organization_and_Summary_of_Si2

Organization and Summary of Significant Accounting Policies Lease Transfers to 3rd party lessors during period (Details) (Lease Agreements [Member], USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Lease Agreements [Member]	'	'	'	'
Third Party Lease Transfers [Line Items]	'	'	'	'
Cash Flows Between Transferor and Transferee, Proceeds from New Transfers	$7.20	$14.60	$28.10	$42.50

Organization_and_Summary_of_Si3

Organization and Summary of Significant Accounting Policies Risks - concentration Revenue and Acct Rec, trading and H-T-M amounts (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Trading Securities	$0	$0	'	'
Cash and cash equivalents	116,190,000	62,313,000	54,818,000	191,762,000
Held-to-maturity Securities, Fair Value	0	0	'	'
Money Market Funds [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash and cash equivalents	64,775,000	38,892,000	'	'
Cash and Cash Equivalents, Fair Value Disclosure	'	$38,891,000	'	'

Organization_and_Summary_of_Si4

Organization and Summary of Significant Accounting Policies Shipping and handling costs (Details) (Shipping, Handling and Transportation Costs [Member], USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Shipping, Handling and Transportation Costs [Member]	'	'	'	'
Component of Operating Other Cost and Expense [Line Items]	'	'	'	'
Other Cost and Expense, Operating	$1.50	$1.20	$4.50	$2.70

Organization_and_Summary_of_Si5

Organization and Summary of Significant Accounting Policies Significant supplier disclosure (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Unusual Risk or Uncertainty [Line Items]	'	'	'	'
Purchases from significant supplier	$8.60	$6.30	$22.50	$17.80

Organization_and_Summary_of_Si6

Organization and Summary of Significant Accounting Policies Income tax disclosure (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Tax Contingency [Line Items]	'	'	'	'
effective tax rate before discrete items	'	'	38.10%	41.50%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	'	'	35.00%	35.00%
Income Tax Expense (Benefit)	$2,987	$4,340	$6,954	$6,703

Organization_and_Summary_of_Si7

Organization and Summary of Significant Accounting Policies Sales of Accounts Receivable (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'	'	'
Document Period End Date	30-Sep-13	'	'	'	'
Lease Transfers In Ending Accounts Receivable	$0.50	'	$0.50	'	'
Lease Agreements [Member]	'	'	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'	'	'
Cash Flows Between Transferor and Transferee, Proceeds from New Transfers	7.2	14.6	28.1	42.5	'
Lease Transfers In Ending Accounts Receivable	'	'	'	'	$0.70

Organization_and_Summary_of_Si8

Organization and Summary of Significant Accounting Policies Accounts Receivable Concentration (Details)	Sep. 30, 2013	Dec. 31, 2012
	customer	customer
Concentration Risk [Line Items]	'	'
customers with 10 % accts rec concentration	0	0

Net_Income_Per_Share_Details

Net Income Per Share (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share [Abstract]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	'	'	1,178,755	2,067,273
Earnings Per Share, Basic [Abstract]	'	'	'	'
Net income	$7,755	$6,920	$17,156	$10,646
Weighted Average Number of Shares Outstanding, Basic	35,133,000	33,193,000	34,499,000	33,316,000
Net income per share-basic	$0.22	$0.21	$0.50	$0.32
Earnings Per Share, Diluted [Abstract]	'	'	'	'
Weighted Average Number of Shares Outstanding, Basic	35,133,000	33,193,000	34,499,000	33,316,000
Dilutive Effect of Employee Stock Plans	$1,057	$875	$967	$925
Weighted Average Number of Shares Outstanding, Diluted	36,190,000	34,068,000	35,466,000	34,241,000
Net income per share - diluted	$0.21	$0.20	$0.48	$0.31

Cash_and_Cash_Equivalents_Shor2

Cash and Cash Equivalents, Short-term Investments and Fair Value of Financial Instruments (Details) avail for sasle securities levels 1-2-3 table (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Cash and Cash Equivalents [Line Items]	'	'
Money Market Fund - daily traded value	$1	'
Cash, Cash Equivalents, and Short-term Investments	116,190,000	62,313,000
Fair Value, Measurements, Recurring [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Cash, Cash Equivalents, and Short-term Investments	64,775,000	38,891,000
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Cash, Cash Equivalents, and Short-term Investments	64,775,000	38,891,000
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Cash, Cash Equivalents, and Short-term Investments	0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Cash, Cash Equivalents, and Short-term Investments	0	0
Money Market Funds [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	'	38,891,000
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	64,775,000	38,891,000
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	'	38,891,000
Cash, Cash Equivalents, and Short-term Investments	64,775,000	'
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	$0	$0

Cash_and_Cash_Equivalents_Shor3

Cash and Cash Equivalents, Short-term Investments and Fair Value of Financial Instruments marketable securities - gain or loss (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Money Market Fund - daily traded value	$1	'	'	'
Cash and cash equivalents, Amortized Cost	116,190,000	62,313,000	54,818,000	191,762,000
Cash, cash equiv and S-T-I: Amortized cost	116,190,000	62,314,000	'	'
Cash, cash equiv and S-T-I: Gross unrealized gains	0	0	'	'
Cash, cash equiv and S-T-I: Gross unrealized losses	0	1,000	'	'
Cash, Cash Equivalents, and Short-term Investments	116,190,000	62,313,000	'	'
Cash [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash and cash equivalents, Amortized Cost	51,415,000	23,422,000	'	'
Cash and cash equivalents - gross unrealized gain	0	0	'	'
Cash and cash equivalents - Gross unrealized losses	0	0	'	'
Cash and Cash Equivalents, Fair Value Disclosure	51,415,000	23,422,000	'	'
Money Market Funds [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash and cash equivalents, Amortized Cost	64,775,000	38,892,000	'	'
Cash and cash equivalents - gross unrealized gain	0	0	'	'
Cash and cash equivalents - Gross unrealized losses	0	1,000	'	'
Cash and Cash Equivalents, Fair Value Disclosure	'	38,891,000	'	'
Cash and Cash Equivalents [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash, Cash Equivalents, and Short-term Investments	116,190,000	62,313,000	'	'
Cash and Cash Equivalents [Member] | Cash [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash and Cash Equivalents, Fair Value Disclosure	51,415,000	23,422,000	'	'
Cash and Cash Equivalents [Member] | Money Market Funds [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash and Cash Equivalents, Fair Value Disclosure	$64,775,000	$38,891,000	'	'

Inventories_Details

Inventories (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventory [Abstract]	'	'
Raw materials	$11,120	$9,994
Work in process	963	385
Finished goods	18,622	16,524
Total	$30,705	$26,903

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and Equipment, Gross	$71,279,000	'	$71,279,000	'	$67,209,000
Accumulated Depreciation	-37,787,000	'	-37,787,000	'	-33,102,000
Property and equipment, net	33,492,000	'	33,492,000	'	34,107,000
Depreciation expense	2,600,000	2,200,000	8,200,000	5,700,000	'
Equipment [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and Equipment, Gross	35,483,000	'	35,483,000	'	32,528,000
Furniture and Fixtures [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and Equipment, Gross	5,149,000	'	5,149,000	'	5,126,000
Leasehold Improvements [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and Equipment, Gross	7,356,000	'	7,356,000	'	6,992,000
Software [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and Equipment, Gross	19,800,000	'	19,800,000	'	19,870,000
Construction in Progress [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and Equipment, Gross	$3,491,000	'	$3,491,000	'	$2,693,000

Net_Investment_in_SalesType_Le2

Net Investment in Sales-Type Leases sales type lease - from min payments to non current investment (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012
Net Investment in Sales-Type Leases [Abstract]	'	'	'
Net minimum lease payments to be received	$18,788,000	$19,665,000	'
Less unearned interest income portion	1,157,000	1,205,000	'
Net investment in sales-type leases	17,631,000	18,460,000	'
Less current portion	5,233,000	5,232,000	'
Non-current net investment in sales-type leases	12,398,000	13,228,000	12,398,000
Allowance for doubtful accounts (Notes), Current	100,000	500,000	'
Allowance for doubtful accounts (Notes), Non-current	$100,000	$100,000	'

Net_Investment_in_SalesType_Le3

Net Investment in Sales-Type Leases (Details) (USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified
Net Investment in Sales-Type Leases [Abstract]	'
2013	$1,640
2014	5,495
2015	4,536
2016	3,341
2017	2,603
Thereafter	1,173
Total	$18,788

Net_Investment_in_SalesType_Le4

Net Investment in Sales-Type Leases Credit loss balances by evaluation method for impairment (Details) (USD $)	Sep. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Mar. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Financing Receivable, Allowance for Credit Losses [Line Items]	'	'	'	'	'	'
Financing Receivable, Allowance for Credit Losses, Individually Evaluated for Impairment	$22	'	$489	'	'	'
Financing Receivable Gross - individually evaluated for impairment	22	'	489	'	'	'
Financing Receivable, Individually Evaluated for Impairment	0	'	0	'	'	'
Financing Receivable, Allowance for Credit Losses, Collectively Evaluated for Impairment	152	'	118	'	'	'
Financing Receivable Gross - collectively evalauated for impairment	17,783	'	18,578	'	'	'
Financing Receivable, Collectively Evaluated for Impairment	17,631	'	18,460	'	'	'
Financing Receivable, Allowance for Credit Losses	174	184	607	637	659	284
Financing Receivable, Gross	17,805	'	19,067	'	'	'
Financing Receivable, Net	$17,631	'	$18,460	'	'	'

Net_Investment_in_SalesType_Le5

Net Investment in Sales-Type Leases allowance credit loss rollforward (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Mar. 31, 2013	Dec. 31, 2012	Mar. 31, 2012
Net Investment in Sales-Type Leases [Abstract]	'	'	'	'	'	'	'
Allowance for Notes, Loans and Financing Receivable, Current	$100,000	'	$100,000	'	'	$500,000	'
Allowance for Notes, Loans and Financing Receivable, Noncurrent	100,000	'	100,000	'	'	100,000	'
Financing Receivable, Allowance for Credit Losses [Roll Forward]	'	'	'	'	'	'	'
Allowance for credit losses, beginning of period	'	'	607,000	284,000	184,000	'	659,000
Current period provision (reversal)	15,000	4,000	34,000	426,000	'	'	'
Direct write-downs charged against the allowance	0	0	-413,000	0	'	'	'
Recoveries of amounts previously charged off	-25,000	-26,000	-54,000	-73,000	'	'	'
Allowance for credit losses, end of period	$174,000	$637,000	$174,000	$637,000	$184,000	'	$659,000

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets Goodwill rollforward by segment (details) (USD $)	3 Months Ended			9 Months Ended
	Sep. 30, 2013	Mar. 31, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Goodwill [Line Items]	'	'	'	'	'
Goodwill, Purchase Accounting Adjustments	'	$100,000	'	'	'
Amortization of Intangible Assets	1,100,000	'	1,100,000	3,200,000	1,800,000
Goodwill [Roll Forward]	'	'	'	'	'
Goodwill, Beginning balance	'	111,407,000	'	111,407,000	'
Goodwill acquired	'	'	'	-64,000	'
Goodwill, Ending balance	111,343,000	'	'	111,343,000	'
Acute Care Solutions [Member]	'	'	'	'	'
Goodwill [Roll Forward]	'	'	'	'	'
Goodwill, Beginning balance	'	28,543,000	'	28,543,000	'
Goodwill acquired	'	'	'	0	'
Goodwill, Ending balance	28,543,000	'	'	28,543,000	'
Non-acute care solutions [Member]	'	'	'	'	'
Goodwill [Roll Forward]	'	'	'	'	'
Goodwill, Beginning balance	'	82,864,000	'	82,864,000	'
Goodwill acquired	'	'	'	-64,000	'
Goodwill, Ending balance	$82,800,000	'	'	$82,800,000	'

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets Finite life intangibles Gross and Net at balance sheet dates (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Sep. 30, 2013
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	$90,477	$90,623
Finite-Lived Intangible Assets, Accumulated Amortization	4,927	8,093
Finite-Lived Intangible Assets, Net	85,550	82,530
Customer Relationships [Member]	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	54,730	54,730
Finite-Lived Intangible Assets, Accumulated Amortization	3,081	4,698
Finite-Lived Intangible Assets, Net	51,649	50,032
acquired technology [Member]	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	27,580	27,580
Finite-Lived Intangible Assets, Accumulated Amortization	1,128	2,230
Finite-Lived Intangible Assets, Net	26,452	25,350
Patents [Member]	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	1,217	1,363
Finite-Lived Intangible Assets, Accumulated Amortization	259	244
Finite-Lived Intangible Assets, Net	958	1,119
Finite-Lived Intangible Asset, Useful Life	'20 years	'
Trade Names [Member]	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	6,890	6,890
Finite-Lived Intangible Assets, Accumulated Amortization	414	861
Finite-Lived Intangible Assets, Net	6,476	6,029
Noncompete Agreements [Member]	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	60	60
Finite-Lived Intangible Assets, Accumulated Amortization	45	60
Finite-Lived Intangible Assets, Net	$15	$0
Finite-Lived Intangible Asset, Useful Life	'3 years	'
Minimum [Member] | Customer Relationships [Member]	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Asset, Useful Life	'5 years	'
Minimum [Member] | acquired technology [Member]	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Asset, Useful Life	'3 years	'
Minimum [Member] | Trade Names [Member]	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Asset, Useful Life	'3 years	'
Maximum [Member] | Customer Relationships [Member]	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Asset, Useful Life	'30 years	'
Maximum [Member] | acquired technology [Member]	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Asset, Useful Life	'20 years	'
Maximum [Member] | Trade Names [Member]	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Asset, Useful Life	'12 years	'

Goodwill_and_Other_Intangible_4

Goodwill and Other Intangible Assets Amortization expense (finite life intangibles) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Goodwill and Intangible Assets Disclosure [Abstract]	'	'	'	'
Amortization of Intangible Assets	$1.10	$1.10	$3.20	$1.80

Goodwill_and_Other_Intangible_5

Goodwill and Other Intangible Assets Future amortizaion of intangibles (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]	'	'
Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year	$1,059	'
2013	4,229	'
2014	4,204	'
2015	3,854	'
2016	3,818	'
Finite-Lived Intangible Assets, Amortization Expense, Year Five	3,711	'
Thereafter	61,655	'
Finite-Lived Intangible Assets, Net	$82,530	$85,550

Goodwill_and_Other_Intangible_6

Goodwill and Other Intangible Assets Indefinite Life Intangibles by class (Details) (USD $)	Dec. 31, 2012	Sep. 30, 2012
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]	'	'
Indefinite-Lived Intangible Assets (Excluding Goodwill)	$0	$0

Accrued_Liabilities_Details

Accrued Liabilities (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accrued Liabilities, Current [Abstract]	'	'
Advance payments from customers	$4,272	$2,829
Accrued Group Purchasing Organization (GPO) fees	2,492	2,278
technologylicensepurchaseobigationcurrent	1,500	1,750
Rebates and lease buyouts	3,379	3,179
Taxes payable	774	555
Other	1,602	1,397
Total	$14,019	$11,988

Deferred_Gross_Profit_Details

Deferred Gross Profit (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred Gross Profit [Abstract]	'	'
Sales of Medication and supply dispensing systems and packaging equipment, which have been delivered and invoiced but not yet installed	$40,919	$30,138
Cost of revenues, excluding installation costs	-15,713	-9,366
Deferred gross profit	$25,206	$20,772

Commitments_Details

Commitments (Details) (USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified
Commitments [Abstract]	'
2013	$1,462
2014	5,722
2015	5,476
2016	5,150
2017	4,468
2018	4,298
Thereafter	16,600
Total	$43,176

Commitments_rented_properties_

Commitments rented properties data (Details) (USD $)

3 Months Ended

12 Months Ended

53 Months Ended

3 Months Ended

12 Months Ended

53 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

In Millions, unless otherwise specified

Sep. 30, 2013

Dec. 31, 2011

Dec. 31, 2012

Jun. 30, 2012

Sep. 30, 2012

Dec. 31, 2012

Jun. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Lease- Mountain View, CA 590 Middlefield road [Member]

Lease- Mountain View, CA 590 Middlefield road [Member]

Lease- Mountain View, CA 590 Middlefield road [Member]

Lease - Milpitas, CA 735 Sycamore Drive [Member]

Lease - Milpitas, CA 735 Sycamore Drive [Member]

Lease - Milpitas, CA 735 Sycamore Drive [Member]

Lease - St. Petersburg, FL 2003 gaudy Bldvd. North [Member]

Lease - St. Petersburg, FL 2003 gaudy Bldvd. North [Member]

Lease - St. Petersburg, FL 2003 gaudy Bldvd. North [Member]

lease - Leeds, United Kingdom [Member]

lease - Leeds, United Kingdom [Member]

sqft

sqft

sqft

sqft

Operating Leased Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Document Period End Date

30-Sep-13

'

'

'

'

'

'

'

'

'

'

'

property subject to operating lease, net rentable area

'

100,000

'

'

46,000

'

'

'

132,500

'

'

16,500

property subject to operating lease term duration

'

'

'

'10 years

'

'

'60 months

'

'

'

'

'

Operating Leases, Rent Expense, Minimum Rentals

'

'

'

$40

'

'

$1.80

$3.90

'

'

$1.20

'

property subject to lease, 1st extension term duration

'

'

'

'

'

'

'

'12 years

'

'

'10 years

'

Property subject to operating lease, 2nd extension term duration

'

'

'60 months

'

'

'

'

'

'

'60 months

'

'

Lease Expiration Date

'

'

'

'

'

'

'

'

'

'

8-Jun-21

'

property subject to lease, 1st extension term duration

'

'

'60 months

'

'

'60 months

'

'

'

'60 months

'0

'

Commitments_supplier_obligatio

Commitments supplier obligation (Details) (USD $)	Sep. 30, 2013
In Millions, unless otherwise specified
Commitments [Abstract]	'
Purchase Commitment, Remaining Minimum Amount Committed	$7.50

Commitments_Fin_48_uncertain_t

Commitments Fin 48 uncertain tax positions in commitments discussion (Details) (USD $)	Sep. 30, 2013
In Millions, unless otherwise specified
Commitments [Abstract]	'
Liability for Uncertain Tax Positions, Noncurrent	$4.70

Contingencies_Details

Contingencies (Details)	9 Months Ended
	Sep. 30, 2012
Product Liability Contingency [Line Items]	'
Net Amount at Risk by Product and Guarantee, Weighted Average Period Remaining	'30 days
Medication Packaging Systems [Member]	'
Product Liability Contingency [Line Items]	'
Net Amount at Risk by Product and Guarantee, Weighted Average Period Remaining	'6 months

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Class of Stock [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	$2,810,000	$2,361,000	$8,423,000	$6,781,000
Treasury Stock, Shares, Acquired	505,137	393,031	'	898,168
Treasury Stock Acquired, Average Cost Per Share	$13.98	$13.49	$15.37	$13.76
Shares Repurchased to date	'	'	5,853,975	'
2008 Repurchase Program [Member]	'	'	'	'
Class of Stock [Line Items]	'	'	'	'
Stock Repurchase Program, Authorized Amount	'	'	90,000,000	'
2012 Repurchase Program [Member]	'	'	'	'
Class of Stock [Line Items]	'	'	'	'
Stock Repurchase Program, Authorized Amount	'	'	50,000,000	'
Performance Shares [Member]	'	'	'	'
Class of Stock [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	$400,000	$200,000	$1,200,000	$800,000

Stock_Option_Plans_and_ShareBa2

Stock Option Plans and Share-Based Compensation Narrative (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2013	Dec. 31, 2011	Sep. 30, 2013	21-May-13	Dec. 31, 2010	Sep. 30, 2013	19-May-09	Sep. 30, 2013	Dec. 31, 2012
In Millions, except Share data, unless otherwise specified		Performance Shares [Member]	Performance Shares [Member]	Employee Stock Option [Member]	2009 Equity Incentive Plan [Member]	2009 Equity Incentive Plan [Member]	2009 Equity Incentive Plan [Member]	2009 Equity Incentive Plan [Member]	2009 Equity Incentive Plan [Member]	2009 Equity Incentive Plan [Member]
									Stock Options [Member]	Stock Options [Member]
										VestingInstallment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	'	140,000	100,000	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	'	'	'	'	'	'	'	2,100,000	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Not Available for Grant For Each Share Granted	'	'	'	'	'	0	1.4	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	'	'	'	'	2,500,000	2,600,000	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'	'	'	'	'	'	'4 years	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Monthly Vesting Installments After Initial Cliff	'	'	'	'	'	'	'	'	'	36
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	'	'	'	'	'	'	'	'	'	'10 years
Common Stock, Capital Shares Reserved for Future Issuance	3,353,608	'	'	'	'	'	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options	'	'	'	$6	'	'	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	'	'1 year 4 months 6 days	'	'2 years 6 months 20 days	'	'	'	'	'	'

Stock_Option_Plans_and_ShareBa3

Stock Option Plans and Share-Based Compensation Stock option rollforward YTD (Details) (USD $)	9 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Common Stock, Capital Shares Reserved for Future Issuance	3,353,608
Employee Stock Option [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$6
Options, shares outstanding- Period start	4,470,000
Options, Outstanding, Wtd Avg Exercise Price - Period start	$14.06
Options, Shares Granted in Period	296,000
Options, Grants in Period, Wtd Avg Exercise Price	$18.10
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	-1,450,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$12.59
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period	-75,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price	$14.40
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	-56,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price	$15.68
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	2,186,000
Options, shares outstanding- Period end	3,185,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$14.85
Options, Outstanding, Wtd Avg Exercise Price - Period end	$15.07

Stock_Option_Plans_and_ShareBa4

Stock Option Plans and Share-Based Compensation Restricted Stock Awards and RSUs rollforward (Details) (USD $)	9 Months Ended		9 Months Ended		9 Months Ended	12 Months Ended			0 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2011	Jun. 30, 2013	Dec. 31, 2012	Jan. 17, 2012
	Restricted Stock [Member]	Restricted Stock [Member]	Restricted Stock Units (RSUs) [Member]	Restricted Stock Units (RSUs) [Member]	Performance Shares [Member]	Performance Shares [Member]	Performance Shares [Member]	Performance Shares [Member]	2011 PSU [Member]
									Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Share-based Awards Other than Options	$0.60	'	$4.80	'	$1.50	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	'7 months 24 days	'	'2 years 2 months	'	'1 year 4 months 6 days	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	52,000	58,000	395,000	389,000	'	'	253,000	175,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$18.43	$14.19	$15.41	$14.09	$13.07	'	'	$11	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	55,000	'	125,000	'	140,000	100,000	'	'	'
PSU shares eligible for vesting based on actual shareholder return	'	'	'	'	'	'	'	'	120,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$18.20	'	$18.12	'	$14.74	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	-61,000	'	-98,000	'	-38,000	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	$14.23	'	$13.90	'	$11.02	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	0	'	-21,000	'	-24,000	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	$0	'	$14.07	'	$0	'	'	'	'

Stock_Option_Plans_and_ShareBa5

Stock Option Plans and Share-Based Compensation Performance based stock units (PSU) (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

12 Months Ended

9 Months Ended

3 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2011

Jun. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Jan. 17, 2012

Mar. 05, 2013

Sep. 30, 2013

Jan. 22, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

PSU program year one [Member]

2011 PSU [Member]

2013 PSU [Member]

2013 PSU [Member]

2012 PSU [Member]

2012 PSU [Member]

Below the 35th percentile ranking [Member]

Below the 35th percentile ranking [Member]

At least 50th percentile (after yr one) [Member]

Below 50th percentile ranking [Member]

Below 50th percentile ranking [Member]

Minimum [Member]

Maximum [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

PSU Program Year Two [Member]

2011 PSU [Member]

PSU Program Year Two [Member]

PSU Program Year Two [Member]

2011 PSU [Member]

Below the 75th percentile ranking [Member]

Below the 75th percentile ranking [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

PSU program year one [Member]

PSU program year one [Member]

Performance Shares [Member]

Performance Shares [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

PSU percentage eligible for time-based vesting

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

0.00%

100.00%

50.00%

50.00%

110.00%

119.00%

Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Share-based Awards Other than Options

'

'

'

'

$1,500,000

'

$1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition

'

'

'

'

'

'

'1 year 4 months 6 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number

'

'

'

'

'

'

'

'

'

253,000

175,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value

'

'

'

'

$13.07

'

$13.07

'

'

'

$11

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period

'

'

'

'

'

'

140,000

'

100,000

'

'

'

'

12,500

125,000

'

125,000

'

'

'

'

'

'

'

PSU shares eligible for vesting based on actual shareholder return

'

'

'

'

'

'

'

'

'

'

'

120,000

120,000

'

'

62,500

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Eligible For Vesting

'

'

'

'

'

'

'

'

'

'

62,500

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

'

'

'

'

'

'

38,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value

'

'

'

'

'

'

$14.74

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value

'

'

'

'

'

'

$11.02

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period

'

'

'

'

'

'

24,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value

'

'

'

'

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Allocated Share-based Compensation Expense

$2,810,000

$2,361,000

$8,423,000

$6,781,000

$400,000

$200,000

$1,200,000

$800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentile ranking of 2011 shareholder return

'

'

'

'

'

'

'

'

'

'

'

76.30%

'

'

'

35.30%

'

'

'

'

'

'

'

'

PSU percentage eligible for vesting based on actual return

'

'

'

'

'

'

'

'

'

'

'

'

120.00%

'

'

50.00%

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based payment Award, Percent Vested in First Year

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

Stock_Option_Plans_and_ShareBa6

Stock Option Plans and Share-Based Compensation PSU performance to vesting table by Program year (Details) (USD $)

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2011

Jun. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Jan. 17, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Jan. 22, 2013

Sep. 30, 2013

Dec. 31, 2012

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Employee Stock [Member]

Employee Stock [Member]

PSU program year one [Member]

PSU program year one [Member]

Below the 35th percentile ranking [Member]

Below 50th percentile ranking [Member]

At least 50th percentile (after yr one) [Member]

Minimum [Member]

Maximum [Member]

2011 PSU [Member]

2011 PSU [Member]

2011 PSU [Member]

2011 PSU [Member]

2011 PSU [Member]

2011 PSU [Member]

2012 PSU [Member]

2012 PSU [Member]

2012 PSU [Member]

Performance Shares [Member]

Vested Performance Shares [Domain]

PSU Program Year Two [Member]

PSU Program Year Two [Member]

PSU Program Year Two [Member]

Below the 75th percentile ranking [Member]

Below the 75th percentile ranking [Member]

Performance Shares [Member]

At The 70th Percentile Ranking [Domain]

Below the 35th percentile ranking [Member]

Below 50th percentile ranking [Member]

Below the 65th percentile ranking [Member]

At or above the 75th percentile ranking [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

PSU program year one [Member]

PSU program year one [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares, Issued

'

'

'

'

'

4,233,557

4,233,557

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number

'

'

'

253,000

175,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value

'

$13.07

'

'

$11

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period

'

140,000

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

125,000

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value

'

$14.74

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

'

38,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value

'

$11.02

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentile ranking of 2011 shareholder return

'

'

'

'

'

'

'

76.30%

'

'

'

'

'

'

'

'

'

'

'

'

35.30%

'

'

PSU percentage eligible for time-based vesting

'

'

'

'

'

'

'

'

'

0.00%

50.00%

100.00%

110.00%

119.00%

'

115.00%

0.00%

50.00%

100.00%

120.00%

'

'

'

PSU percentage eligible for vesting based on actual return

'

'

'

'

'

'

'

'

'

'

'

'

'

'

120.00%

'

'

'

'

'

50.00%

'

'

PSU shares eligible for vesting based on actual shareholder return

'

'

'

'

'

'

'

120,000

10,000

'

'

'

'

'

120,000

'

'

'

'

'

62,500

'

'

Share-based Compensation Arrangement by Share-based Payment Award, First Year Share Vesting Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25.00%

'

Share-based Compensation Arrangement by Share-based payment Award, Percent Vested in First Year

'

'

'

'

'

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period

'

24,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Capital Shares Reserved for Future Issuance

3,353,607.80

'

'

'

'

1,097,998

1,097,998

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

'

'

'

'

'

193,719

450,713

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock_Option_Plans_and_ShareBa7

Stock Option Plans and Share-Based Compensation ESPP- Employee stock purchase plan (Details) (USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Common Stock, Capital Shares Reserved for Future Issuance	3,353,607.80	3,353,607.80
Employee Stock [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
ESPP max percent of earnings contributable	'	15.00%
ESPP max annual contribution	'	$25,000
ESPP purchase price as percent of begin and-or ending fair value	'	85.00%
Shares, Issued	4,233,557	4,233,557
Common Stock, Capital Shares Reserved for Future Issuance	1,097,998	1,097,998
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	193,719	450,713

Stock_Option_Plans_and_ShareBa8

Stock Option Plans and Share-Based Compensation Stock expense by P&L caption (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	$2,810	$2,361	$8,423	$6,781
Cost of Sales [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	325	275	955	776
Research and Development Expense [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	405	232	1,019	686
Selling, General and Administrative Expenses [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	$2,080	$1,854	$6,449	$5,319

Business_Acquisition_Business_

Business Acquisition Business Acquisition (Details) (USD $)

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

3 Months Ended

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

20-May-12

Oct. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

20-May-12

Sep. 30, 2013

Sep. 30, 2013

20-May-12

MTS-Medication Technologies [Member]

MTS-Medication Technologies [Member]

MTS-Medication Technologies [Member]

MTS-Medication Technologies [Member]

Minimum [Member]

Maximum [Member]

Cost Of Product Revenue [Member]

MTS-Medication Technologies [Member]

MTS-Medication Technologies [Member]

MTS-Medication Technologies [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Business acquisition cash paid at closing

'

'

'

'

'

'

'

'

'

$158,300,000

'

'

'

business acquisition sellers escrow account

'

'

'

'

'

'

'

'

'

13,500,000

'

'

'

Business Acquisition Final adjustment amount, estimated

'

'

'

'

'

'

'

'

1,800,000

'

'

'

'

Business Acquisition, Cash Received Through Release of Escrow Funds

'

'

'

'

'

'

300,000

'

'

'

'

'

'

Cash including restricted cash

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

Business Combination, Acquired Receivables, Fair Value

'

'

'

'

'

7,403,000

'

'

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Current Assets, Inventory

'

'

'

'

'

11,726,000

'

'

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Current Assets, Prepaid Expense and Other Assets

'

'

'

'

'

2,894,000

'

'

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Current Assets

'

'

'

'

'

24,023,000

'

'

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Property, Plant and Equipment

'

'

'

'

'

'

'

1,300,000

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Intangible Assets Other than Goodwill

'

'

'

'

'

'

'

-400,000

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Goodwill Amount

'

'

'

'

'

82,800,000

'

'

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Other Noncurrent Assets

'

'

'

'

'

308,000

'

'

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Assets Acquired

'

'

'

'

'

200,838,000

'

'

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Current Liabilities

'

'

'

'

'

-7,917,000

'

'

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Deferred Tax Liabilities, Noncurrent

'

'

'

'

'

-33,386,000

'

'

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Noncurrent Liabilities

'

'

'

'

'

-1,223,000

'

'

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Assets Acquired (Liabilities Assumed), Net

'

'

'

'

'

158,312,000

'

'

'

'

'

'

'

Business Combination, Consideration Transferred

'

'

'

'

'

158,312,000

'

'

'

158,300,000

'

'

'

Business Combination, Acquired Receivables, Gross Contractual Amount

'

'

'

'

'

'

'

'

'

7,600,000

'

'

'

Business Acquisitions Receivablesnot expected collectible

'

'

'

'

'

'

'

'

'

-200,000

'

'

'

Business Combination, Step Acquisition, Inventory Adjustment

'

'

'

'

'

'

'

'

'

'

'

'

1,600,000

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

'

'

'

'

'

'

'

'25 years 1 month 21 days

'

'

'12 years

'30 years

'

Goodwill, Purchase Accounting Adjustments

'

100,000

'

'

'

'

'

900,000

'

'

'

'

'

Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent

$0

'

$0

($65,000)

$65,000

'

'

'

'

'

'

'

'

Business_Acquisition_Bus_acqui

Business Acquisition Bus acquisition - Table of acquired Intangibles (Details) (USD $)

20-May-12

Sep. 30, 2013

20-May-12

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

In Thousands, unless otherwise specified

MTS-Medication Technologies [Member]

MTS-Medication Technologies [Member]

MTS-Medication Technologies [Member]

MTS-Medication Technologies [Member]

MTS-Medication Technologies [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Trade Names [Member]

Customer Relationships [Member]

acquired technology [Member]

Trade Names [Member]

Customer Relationships [Member]

acquired technology [Member]

MTS-Medication Technologies [Member]

MTS-Medication Technologies [Member]

Trade Names [Member]

Customer Relationships [Member]

acquired technology [Member]

MTS-Medication Technologies [Member]

MTS-Medication Technologies [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Acquired Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Current Assets, Cash and Cash Equivalents

$2,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Current Assets, Receivables

7,403

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Current Assets, Inventory

11,726

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Current Assets, Prepaid Expense and Other Assets

2,894

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Property, Plant and Equipment

9,807

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Intangible Assets Other than Goodwill

83,900

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Goodwill Amount

82,800

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Other Noncurrent Assets

308

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Assets Acquired

200,838

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Current Liabilities

7,917

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Deferred Tax Liabilities, Noncurrent

33,386

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Asset, Useful Life

'

'

'

'12 years

'

'20 years

'3 years

'5 years

'3 years

'

'28 years

'12 years

'30 years

'20 years

'

'30 years

Acquired Finite-lived Intangible Asset, Amount

'

83,900

'

6,800

50,500

26,600

'

'

'

'

'

'

'

'

'

'

Expected amortization of acquired intangibles first year

'

3,604

'

567

1,707

1,330

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Other Noncurrent Liabilities

1,223

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Assets Acquired (Liabilities Assumed), Net

158,312

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Cost of Acquired Entity, Cash Paid

$158,312

'

$158,300

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

'

'25 years 1 month 21 days

'

'

'

'

'

'

'

'12 years

'

'

'

'

'30 years

'

Business_Acquisition_Acquiree_

Business Acquisition Acquiree operating results to date since acquisition (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Business Acquisition [Line Items]	'	'	'	'
Revenues	$94,039	$84,331	$274,835	$223,858
Net income	$7,755	$6,920	$17,156	$10,646

Business_Acquisition_Bus_Acq_t

Business Acquisition Bus Acq - tranasaction costs expense in period (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2012
Business Acquisition [Line Items]	'
Business Combination, Acquisition Related Costs	$3.20

Segments_Details

Segments (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Segment Reporting Information [Line Items]	'	'	'	'	'
Depreciation and amortization	$4,488	$3,914	$13,732	$9,247	'
Segment Reporting Information, Net Assets	505,984	'	505,984	'	441,819
Revenues	94,039	84,331	274,835	223,858	'
Cost of Revenue	41,999	38,244	128,060	102,646	'
Gross profit	52,040	46,087	146,775	121,212	'
Gross Margin Percentage	55.30%	54.70%	53.40%	54.10%	'
Operating Expenses	41,323	34,861	122,531	103,920	'
Income from operations	10,717	11,226	24,244	17,292	'
Operating margin percentage	11.40%	13.30%	8.80%	7.70%	'
Interest and other income (expense), net	25	34	-134	57	'
Income before provision for income taxes	10,742	11,260	24,110	17,349	'
Provision for income taxes	2,987	4,340	6,954	6,703	'
Net income	7,755	6,920	17,156	10,646	'
Segment Reporting Information, Expenditures for Additions to Long-Lived Assets	2,056	5,472	7,807	9,559	'
Acute Care Solutions [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Depreciation and amortization	2,805	2,072	8,351	6,538	'
Segment Reporting Information, Net Assets	284,067	'	284,067	'	235,186
Revenues	70,640	64,394	204,750	191,295	'
Cost of Revenue	28,662	26,920	87,784	82,859	'
Gross profit	41,978	37,474	116,966	108,436	'
Gross Margin Percentage	59.40%	58.20%	57.10%	56.70%	'
Operating Expenses	32,908	29,070	96,048	94,167	'
Income from operations	9,070	8,404	20,918	14,269	'
Operating margin percentage	12.80%	13.10%	10.20%	7.50%	'
Segment Reporting Information, Expenditures for Additions to Long-Lived Assets	1,311	4,940	3,329	8,947	'
Non-acute care solutions [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Depreciation and amortization	1,683	1,842	5,381	2,709	'
Segment Reporting Information, Net Assets	221,917	'	221,917	'	206,633
Revenues	23,399	19,937	70,085	32,563	'
Cost of Revenue	13,337	11,324	40,276	19,787	'
Gross profit	10,062	8,613	29,809	12,776	'
Gross Margin Percentage	43.00%	43.20%	42.50%	39.20%	'
Operating Expenses	8,415	5,791	26,483	9,753	'
Income from operations	1,647	2,822	3,326	3,023	'
Operating margin percentage	7.00%	14.20%	4.70%	9.30%	'
Segment Reporting Information, Expenditures for Additions to Long-Lived Assets	$745	$532	$4,478	$612	'

Asset_Impairment_Details

Asset Impairment (Details) (USD $)	3 Months Ended	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2013	Sep. 30, 2013	Sep. 30, 2012
Asset Impairment [Abstract]	'	'	'
Asset Impairment Charges	$1,759	$1,759	$0
Change in accounting estimate impact on dilted eps	$0.03	'	'

Credit_Agreement_Details

Credit Agreement (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013
Line of Credit Facility [Line Items]	'
Line of Credit Facility, Maximum Borrowing Capacity	$75
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.25%
Potential Increase in Aggregate Commitments [Member]	'
Line of Credit Facility [Line Items]	'
Line of Credit Facility, Maximum Borrowing Capacity	25
Letter of Credit [Member]	'
Line of Credit Facility [Line Items]	'
Line of Credit Facility, Maximum Borrowing Capacity	$10
Eurodollar Rate [Member]	'
Line of Credit Facility [Line Items]	'
Debt Instrument, Basis Spread on Variable Rate	1.75%
Federal Funds Rate [Member]	'
Line of Credit Facility [Line Items]	'
Debt Instrument, Basis Spread on Variable Rate	0.50%
LIBOR [Member]	'
Line of Credit Facility [Line Items]	'
Debt Instrument, Basis Spread on Variable Rate	1.75%